SB 950: Health care coverage: dementia.
- Session Year: 2025-2026
- House: Senate
- Latest Version Date: 2026-09-27
Current Status:
Passed
(2026-09-27: Chaptered by Secretary of State. Chapter 662, Statutes of 2026.)
Introduced
In Committee
Awaiting First Chamber Vote
Passed First Chamber
In Committee
Awaiting Second Chamber Vote
Passed Second Chamber
Enacted
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the acts requirements a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law prohibits specified health care service plan contracts and disability insurance policies from excluding persons covered by the plan from receiving benefits if they are diagnosed as having any significant destruction of brain tissue with resultant loss of brain function, including Alzheimers disease.
This bill would require a health care service plan contract or health insurance policy that is issued, amended, or renewed on or after January 1, 2027, to include coverage for all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimers disease or other medical conditions affecting memory. On and after January 1, 2027, the bill would prohibit a health care service plan or health insurer from imposing step therapy protocols as a prerequisite to authorizing that coverage, except as provided. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the acts requirements a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law prohibits specified health care service plan contracts and disability insurance policies from excluding persons covered by the plan from receiving benefits if they are diagnosed as having any significant destruction of brain tissue with resultant loss of brain function, including Alzheimers disease.
This bill would require a health care service plan contract or health insurance policy that is issued, amended, or renewed on or after January 1, 2027, to include coverage for all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimers disease or other medical conditions affecting memory. On and after January 1, 2027, the bill would prohibit a health care service plan or health insurer from imposing step therapy protocols as a prerequisite to authorizing that coverage, except as provided. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the acts requirements a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law prohibits specified health care service plan contracts and disability insurance policies from excluding persons covered by the plan from receiving benefits if they are diagnosed as having any significant destruction of brain tissue with resultant loss of brain function, including Alzheimers disease.
This bill would require a health care service plan contract or health insurance policy that is issued, amended, or renewed on or after January 1, 2027, to include coverage for all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimers disease or other related dementia. medical conditions affecting memory. On and after January 1, 2027, the bill would prohibit a health care service plan or health insurer from imposing step therapy protocols as a prerequisite to authorizing that coverage, except as provided. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the acts requirements a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law prohibits specified health care service plan contracts and disability insurance policies from excluding persons covered by the plan from receiving benefits if they are diagnosed as having any significant destruction of brain tissue with resultant loss of brain function, including Alzheimers disease.
This bill would require a health care service plan contract or health insurance policy that is issued, amended, or renewed on or after January 1, 2027, to include coverage for all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimers disease or other related dementia. Under the bill, contracts and policies would not be required to cover drugs or treatments that are pharmaceutically equivalent drug products if the FDA approves more than one. On and after January 1, 2027, the bill would prohibit a health care service plan or health insurer from imposing step therapy protocols as a prerequisite to authorizing that coverage, except as provided. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the acts requirements a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law prohibits specified health care service plan contracts and disability insurance policies from excluding persons covered by the plan from receiving benefits if they are diagnosed as having any significant destruction of brain tissue with resultant loss of brain function, including Alzheimers disease.
This bill would require a health care service plan contract or health insurance policy that is issued, amended, or renewed on or after January 1, 2027, to include coverage for all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimers disease or other related dementia. Under the bill, contracts and policies would not be required to cover drugs or treatments that are pharmaceutically equivalent drug products if the FDA approves more than one. On and after January 1, 2027, the bill would prohibit a health care service plan or health insurer from imposing step therapy protocols as a prerequisite to authorizing that coverage, except as provided. The bill would require a health care service plan or health insurer that, as a medical benefit, covers nonself-administered treatments approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory to also include those nonself-administered treatments as an outpatient prescription drug benefit. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the acts requirements a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law prohibits specified health care service plan contracts and disability insurance policies from excluding persons covered by the plan from receiving benefits if they are diagnosed as having any significant destruction of brain tissue with resultant loss of brain function, including Alzheimers disease.
This bill would require a health care service plan contract or health insurance policy that is issued, amended, or renewed on or after January 1, 2027, to include coverage for all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimers disease or other related dementia. On and after January 1, 2027, the bill would prohibit a health care service plan or health insurer from imposing step therapy protocols as a prerequisite to authorizing that coverage, except as provided. The bill would require a health care service plan or health insurer that, as a medical benefit, covers nonself-administered treatments approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory to also include those nonself-administered treatments as an outpatient prescription drug benefit. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
(a)(1)A health care service plan contract that is issued, amended, or renewed on or after January 1, 2027, shall include coverage for all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimers disease or other medical conditions affecting memory. Medically necessary treatments or medications include, but are not limited to, those that reduce clinical decline.
(2)Medically necessary treatments or medications covered pursuant to paragraph (1) include those administered through a medical benefit, an outpatient prescription drug benefit to the extent the health care service plan contract covers outpatient prescription drugs, or both.
(b)(1)On and after January 1, 2027, a health care service plan shall not impose step therapy protocols as a prerequisite to authorizing coverage of medically necessary treatments or medications approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory, except as provided in paragraph (3). For purposes of this section, step therapy protocol means a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed.
(2)For purposes of this subdivision, step therapy is prohibited for both self-administered drugs and physician-administered drugs, except as provided in paragraph (3).
(3)If the FDA has approved one or more types of treatment for Alzheimers disease or other medical conditions affecting memory, this section does not require a health care service plan to cover all types of treatment for Alzheimers disease or other medical conditions affecting memory without step therapy, if at least one antiamyloid therapy is covered without step therapy.
(c)Except as provided in subdivision (b), this section does not prohibit a health care service plan from applying utilization management, including prior authorization, to determine the medical necessity for treatment of Alzheimers disease or other medical conditions affecting memory if appropriateness and medical necessity determinations are made in the same manner as those determinations are made for the treatment of any other illness, condition, or disorder covered by the plan contract.
(d)Coverage criteria for FDA-approved treatments described in this section shall not be more restrictive than the FDA-approved indications for those treatments.
(e)For purposes of this section, authorization for a medically necessary treatment approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory shall be considered an exigent circumstance, consistent with the requirements of Section 1367.241.
(f)This section does not apply to the following:
(1)A specialized health care service plan contract that covers only dental or vision benefits or a Medicare supplement contract.
(2)A Medi-Cal managed care plan contract with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14591) of Part 3 of Division 9 of the Welfare and Institutions Code.
SEC. 2.Section 10123.175 is added to the Insurance Code, to read:10123.175.(a)(1)A health insurance policy that is issued, amended, or renewed on or after January 1, 2027, shall include coverage for all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimers disease or other medical conditions affecting memory. Medically necessary treatments or medications include, but are not limited to, those that reduce clinical decline.
(2)Medically necessary treatments or medications covered pursuant to paragraph (1) include those administered through a medical benefit, an outpatient prescription drug benefit to the extent the health insurance policy covers outpatient prescription drugs, or both.
(b)(1)On and after January 1, 2027, a health insurer shall not impose step therapy protocols as a prerequisite to authorizing coverage of medically necessary treatments or medications approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory, except as provided in paragraph (3). For purposes of this section, step therapy protocol means a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed.
(2)For purposes of this subdivision, step therapy is prohibited for both self-administered drugs and physician-administered drugs, except as provided in paragraph (3).
(3)If the FDA has approved one or more types of treatment for Alzheimers disease or other medical conditions affecting memory, this section does not require a health insurer to cover all types of treatment for Alzheimers disease or other medical conditions affecting memory without step therapy, if at least one antiamyloid therapy is covered without step therapy.
(c)Except as provided in subdivision (b), this section does not prohibit a health insurer from applying utilization management, including prior authorization, to determine the medical necessity for treatment of Alzheimers disease or other medical conditions affecting memory if appropriateness and medical necessity determinations are made in the same manner as those determinations are made for the treatment of any other illness, condition, or disorder covered by the plan contract.
(d)Coverage criteria for FDA-approved treatments described in this section shall not be more restrictive than the FDA-approved indications for those treatments.
(e)For purposes of this section, authorization for a medically necessary treatment approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory shall be considered an exigent circumstance, consistent with the requirements of Section 10123.191.
(f)This section does not apply to vision-only, dental-only, accident-only, specified disease, hospital indemnity, or Medicare supplement insurance policies.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)(1)A health care service plan contract that is issued, amended, or renewed on or after January 1, 2027, shall include coverage for all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimers disease or other medical conditions affecting memory. Medically necessary treatments or medications include, but are not limited to, those that reduce clinical decline.
(2)Medically necessary treatments or medications covered pursuant to paragraph (1) include those administered through a medical benefit, an outpatient prescription drug benefit to the extent the health care service plan contract covers outpatient prescription drugs, or both.
(b)(1)On and after January 1, 2027, a health care service plan shall not impose step therapy protocols as a prerequisite to authorizing coverage of medically necessary treatments or medications approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory, except as provided in paragraph (3). For purposes of this section, step therapy protocol means a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed.
(2)For purposes of this subdivision, step therapy is prohibited for both self-administered drugs and physician-administered drugs, except as provided in paragraph (3).
(3)If the FDA has approved one or more types of treatment for Alzheimers disease or other medical conditions affecting memory, this section does not require a health care service plan to cover all types of treatment for Alzheimers disease or other medical conditions affecting memory without step therapy, if at least one antiamyloid therapy is covered without step therapy.
(c)Except as provided in subdivision (b), this section does not prohibit a health care service plan from applying utilization management, including prior authorization, to determine the medical necessity for treatment of Alzheimers disease or other medical conditions affecting memory if appropriateness and medical necessity determinations are made in the same manner as those determinations are made for the treatment of any other illness, condition, or disorder covered by the plan contract.
(d)Coverage criteria for FDA-approved treatments described in this section shall not be more restrictive than the FDA-approved indications for those treatments.
(e)For purposes of this section, authorization for a medically necessary treatment approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory shall be considered an exigent circumstance, consistent with the requirements of Section 1367.241.
(f)This section does not apply to the following:
(1)A specialized health care service plan contract that covers only dental or vision benefits or a Medicare supplement contract.
(2)A Medi-Cal managed care plan contract with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14591) of Part 3 of Division 9 of the Welfare and Institutions Code.
SEC. 2.Section 10123.175 is added to the Insurance Code, to read:10123.175.(a)(1)A health insurance policy that is issued, amended, or renewed on or after January 1, 2027, shall include coverage for all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimers disease or other medical conditions affecting memory. Medically necessary treatments or medications include, but are not limited to, those that reduce clinical decline.
(2)Medically necessary treatments or medications covered pursuant to paragraph (1) include those administered through a medical benefit, an outpatient prescription drug benefit to the extent the health insurance policy covers outpatient prescription drugs, or both.
(b)(1)On and after January 1, 2027, a health insurer shall not impose step therapy protocols as a prerequisite to authorizing coverage of medically necessary treatments or medications approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory, except as provided in paragraph (3). For purposes of this section, step therapy protocol means a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed.
(2)For purposes of this subdivision, step therapy is prohibited for both self-administered drugs and physician-administered drugs, except as provided in paragraph (3).
(3)If the FDA has approved one or more types of treatment for Alzheimers disease or other medical conditions affecting memory, this section does not require a health insurer to cover all types of treatment for Alzheimers disease or other medical conditions affecting memory without step therapy, if at least one antiamyloid therapy is covered without step therapy.
(c)Except as provided in subdivision (b), this section does not prohibit a health insurer from applying utilization management, including prior authorization, to determine the medical necessity for treatment of Alzheimers disease or other medical conditions affecting memory if appropriateness and medical necessity determinations are made in the same manner as those determinations are made for the treatment of any other illness, condition, or disorder covered by the plan contract.
(d)Coverage criteria for FDA-approved treatments described in this section shall not be more restrictive than the FDA-approved indications for those treatments.
(e)For purposes of this section, authorization for a medically necessary treatment approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory shall be considered an exigent circumstance, consistent with the requirements of Section 10123.191.
(f)This section does not apply to vision-only, dental-only, accident-only, specified disease, hospital indemnity, or Medicare supplement insurance policies.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)(1)A health care service plan contract that is issued, amended, or renewed on or after January 1, 2027, shall include coverage for all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimers disease or other related dementia. medical conditions affecting memory. Medically necessary treatments or medications include, but are not limited to, those that reduce clinical decline.
(2)Medically necessary treatments or medications covered pursuant to paragraph (1) include those administered through a medical benefit, an outpatient prescription drug benefit to the extent the health care service plan contract covers outpatient prescription drugs, or both.
(b)(1)On and after January 1, 2027, a health care service plan shall not impose step therapy protocols as a prerequisite to authorizing coverage of medically necessary treatments or medications approved by the FDA for the treatment of Alzheimers disease, disease or other medical conditions affecting memory, except as provided in paragraph (3). For purposes of this section, step therapy protocol means a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed.
(2)For purposes of this subdivision, step therapy is prohibited for both self-administered drugs and physician-administered drugs, except as provided in paragraph (3).
(3)If the FDA has approved one or more types of treatment for Alzheimers disease or other medical conditions affecting memory, this section does not require a health care service plan to cover all types of treatment for Alzheimers disease or other medical conditions affecting memory without step therapy, if at least one antiamyloid therapy is covered without step therapy.
(c)This(c)Except as provided in subdivision (b), this section does not prohibit a health care service plan from applying utilization management, including prior authorization, to determine the medical necessity for treatment of Alzheimers disease or other medical conditions affecting memory if appropriateness and medical necessity determinations are made in the same manner as those determinations are made for the treatment of any other illness, condition, or disorder covered by the plan contract.
(d)Coverage criteria for FDA-approved treatments described in this section shall not be more restrictive than the FDA-approved indications for those treatments.
(e)For purposes of this section, authorization for a medically necessary treatment approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory shall be considered an exigent circumstance, consistent with the requirements of Section 1367.241.
(f)This section does not apply to the following:
(1)A specialized health care service plan contract that covers only dental or vision benefits or a Medicare supplement contract.
(2)A Medi-Cal managed care plan contract with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14591) of Part 3 of Division 9 of the Welfare and Institutions Code.
SEC. 2.Section 10123.175 is added to the Insurance Code, to read:10123.175.(a)(1)A health insurance policy that is issued, amended, or renewed on or after January 1, 2027, shall include coverage for all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimers disease or other related dementia. medical conditions affecting memory. Medically necessary treatments or medications include, but are not limited to, those that reduce clinical decline.
(2)Medically necessary treatments or medications covered pursuant to paragraph (1) include those administered through a medical benefit, an outpatient prescription drug benefit to the extent the health insurance policy covers outpatient prescription drugs, or both.
(b)(1)On and after January 1, 2027, a health insurer shall not impose step therapy protocols as a prerequisite to authorizing coverage of medically necessary treatments or medications approved by the FDA for the treatment of Alzheimers disease, disease or other medical conditions affecting memory, except as provided in paragraph (3). For purposes of this section, step therapy protocol means a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed.
(2)For purposes of this subdivision, step therapy is prohibited for both self-administered drugs and physician-administered drugs, except as provided in paragraph (3).
(3)If the FDA has approved one or more types of treatment for Alzheimers disease or other medical conditions affecting memory, this section does not require a health insurer to cover all types of treatment for Alzheimers disease or other medical conditions affecting memory without step therapy, if at least one antiamyloid therapy is covered without step therapy.
(c)This(c)Except as provided in subdivision (b), this section does not prohibit a health insurer from applying utilization management, including prior authorization, to determine the medical necessity for treatment of Alzheimers disease or other medical conditions affecting memory if appropriateness and medical necessity determinations are made in the same manner as those determinations are made for the treatment of any other illness, condition, or disorder covered by the plan contract.
(d)Coverage criteria for FDA-approved treatments described in this section shall not be more restrictive than the FDA-approved indications for those treatments.
(e)For purposes of this section, authorization for a medically necessary treatment approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory shall be considered an exigent circumstance, consistent with the requirements of Section 10123.191.
(f)This section does not apply to vision-only, dental-only, accident-only, specified disease, hospital indemnity, or Medicare supplement insurance policies.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)(1)A health care service plan contract that is issued, amended, or renewed on or after January 1, 2027, shall include coverage for all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimers disease or other related dementia. Medically necessary treatments or medications include, but are not limited to, those that reduce clinical decline.
(2)Medically necessary treatments or medications covered pursuant to paragraph (1) include those administered through a medical benefit, an outpatient prescription drug benefit to the extent the health care service plan contract covers outpatient prescription drugs, or both.
(3)Coverage for all medically necessary treatment or medications pursuant to paragraph (1) does not require a health care service plan contract to cover drugs or treatments that are pharmaceutically equivalent drug products if the FDA approves more than one medication or treatment that are pharmaceutically equivalent drug products, unless otherwise required by law.(b)(1)On and after January 1, 2027, a health care service plan shall not impose step therapy protocols as a prerequisite to authorizing coverage of medically necessary treatments or medications approved by the FDA for the treatment of Alzheimers disease, except as provided in paragraph (3). For purposes of this section, step therapy protocol means a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed.
(2)For purposes of this subdivision, step therapy is prohibited for both self-administered drugs and physician-administered drugs, except as provided in paragraph (3).
(3)If the FDA has approved one or more types of treatment for Alzheimers disease or other medical conditions affecting memory, this section does not require a health care service plan to cover all types of treatment for Alzheimers disease or other medical conditions affecting memory without step therapy, if at least one antiamyloid therapy is covered without step therapy.
(c)This section does not prohibit a health care service plan from applying utilization management, including prior authorization, to determine the medical necessity for treatment of Alzheimers or other medical conditions affecting memory if appropriateness and medical necessity determinations are made in the same manner as those determinations are made for the treatment of any other illness, condition, or disorder covered by the plan contract.
(d)Coverage criteria for FDA-approved treatments described in this section shall not be more restrictive than the FDA-approved indications for those treatments.
(e)For purposes of this section, authorization for a medically necessary treatment approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory shall be considered an exigent circumstance, consistent with the requirements of Section 1367.241.
(f)This section does not apply to the following:
(1)A specialized health care service plan contract that covers only dental or vision benefits or a Medicare supplement contract.
(2)A Medi-Cal managed care plan contract with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14591) of Part 3 of Division 9 of the Welfare and Institutions Code.
SEC. 2.Section 10123.175 is added to the Insurance Code, to read:10123.175.(a)(1)A health insurance policy that is issued, amended, or renewed on or after January 1, 2027, shall include coverage for all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimers disease or other related dementia. Medically necessary treatments or medications include, but are not limited to, those that reduce clinical decline.
(2)Medically necessary treatments or medications covered pursuant to paragraph (1) include those administered through a medical benefit, an outpatient prescription drug benefit to the extent the health insurance policy covers outpatient prescription drugs, or both.
(3)Coverage for all medically necessary treatment or medications pursuant to paragraph (1) does not require a health insurance policy to cover drugs or treatments that are pharmaceutically equivalent drug products if the FDA approves more than one medication or treatment that are pharmaceutically equivalent drug products, unless otherwise required by law.(b)(1)On and after January 1, 2027, a health insurer shall not impose step therapy protocols as a prerequisite to authorizing coverage of medically necessary treatments or medications approved by the FDA for the treatment of Alzheimers disease, except as provided in paragraph (3). For purposes of this section, step therapy protocol means a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed.
(2)For purposes of this subdivision, step therapy is prohibited for both self-administered drugs and physician-administered drugs, except as provided in paragraph (3).
(3)If the FDA has approved one or more types of treatment for Alzheimers disease or other medical conditions affecting memory, this section does not require a health insurer to cover all types of treatment for Alzheimers disease or other medical conditions affecting memory without step therapy, if at least one antiamyloid therapy is covered without step therapy.
(c)This section does not prohibit a health insurer from applying utilization management, including prior authorization, to determine the medical necessity for treatment of Alzheimers or other medical conditions affecting memory if appropriateness and medical necessity determinations are made in the same manner as those determinations are made for the treatment of any other illness, condition, or disorder covered by the plan contract.
(d)Coverage criteria for FDA-approved treatments described in this section shall not be more restrictive than the FDA-approved indications for those treatments.
(e)For purposes of this section, authorization for a medically necessary treatment approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory shall be considered an exigent circumstance, consistent with the requirements of Section 10123.191.
(f)This section does not apply to vision-only, dental-only, accident-only, specified disease, hospital indemnity, or Medicare supplement insurance policies.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)(1)A health care service plan contract that is issued, amended, or renewed on or after January 1, 2027, shall include coverage for all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimers disease or other related dementia. Medically necessary treatments or medications include, but are not limited to, those that reduce clinical decline.
(2)Medically necessary treatments or medications covered pursuant to paragraph (1) include those administered through a medical benefit, an outpatient prescription drug benefit to the extent the health care service plan contract covers outpatient prescription drugs, or both.
(3)Coverage for all medically necessary treatment or medications pursuant to paragraph (1) does not require a health care service plan contract to cover drugs or treatments that are pharmaceutically equivalent drug products if the FDA approves more than one medication or treatment that are pharmaceutically equivalent drug products, unless otherwise required by law.
(b)(1)On and after January 1, 2027, a health care service plan shall not impose step therapy protocols as a prerequisite to authorizing coverage of medically necessary treatments or medications approved by the FDA for the treatment of Alzheimers disease, except as provided in paragraph (3). For purposes of this section, step therapy protocol means a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed.
(2)For purposes of this subdivision, step therapy is prohibited for both self-administered drugs and physician-administered drugs, except as provided in paragraph (3).
(3)If the FDA has approved one or more types of treatment for Alzheimers disease or other medical conditions affecting memory, this section does not require a health care service plan to cover all types of treatment for Alzheimers disease or other medical conditions affecting memory without step therapy, if at least one antiamyloid therapy is covered without step therapy.
(c)This section does not prohibit a health care service plan from applying utilization management, including prior authorization, to determine the medical necessity for treatment of Alzheimers or other medical conditions affecting memory if appropriateness and medical necessity determinations are made in the same manner as those determinations are made for the treatment of any other illness, condition, or disorder covered by the plan contract.
(d)Coverage criteria for FDA-approved treatments described in this section shall not be more restrictive than the FDA-approved indications for those treatments.
(e)Notwithstanding paragraph (3) of subdivision (b), a health care service plan that, as a medical benefit, covers nonself-administered treatments approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory shall also include those nonself-administered treatments approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory as an outpatient prescription drug benefit.(f)(e)For purposes of this section, a health care service plan shall maintain an expeditious process by which prescribing providers may obtain authorization for a medically necessary treatment approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory, memory shall be considered an exigent circumstance, consistent with the requirements of this article. Section 1367.241.
(g)(f)This section does not apply to the following:
(1)A specialized health care service plan contract that covers only dental or vision benefits or a Medicare supplement contract.
(2)A Medi-Cal managed care plan contract with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14591) of Part 3 of Division 9 of the Welfare and Institutions Code.
SEC. 2.Section 10123.175 is added to the Insurance Code, to read:10123.175.(a)(1)A health insurance policy that is issued, amended, or renewed on or after January 1, 2027, shall include coverage for all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimers disease or other related dementia. Medically necessary treatments or medications include, but are not limited to, those that reduce clinical decline.
(2)Medically necessary treatments or medications covered pursuant to paragraph (1) include those administered through a medical benefit, an outpatient prescription drug benefit to the extent the health insurance policy covers outpatient prescription drugs, or both.
(3)Coverage for all medically necessary treatment or medications pursuant to paragraph (1) does not require a health insurance policy to cover drugs or treatments that are pharmaceutically equivalent drug products if the FDA approves more than one medication or treatment that are pharmaceutically equivalent drug products, unless otherwise required by law.
(b)(1)On and after January 1, 2027, a health insurer shall not impose step therapy protocols as a prerequisite to authorizing coverage of medically necessary treatments or medications approved by the FDA for the treatment of Alzheimers disease, except as provided in paragraph (3). For purposes of this section, step therapy protocol means a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed.
(2)For purposes of this subdivision, step therapy is prohibited for both self-administered drugs and physician-administered drugs, except as provided in paragraph (3).
(3)If the FDA has approved one or more types of treatment for Alzheimers disease or other medical conditions affecting memory, this section does not require a health insurer to cover all types of treatment for Alzheimers disease or other medical conditions affecting memory without step therapy, if at least one antiamyloid therapy is covered without step therapy.
(c)This section does not prohibit a health insurer from applying utilization management, including prior authorization, to determine the medical necessity for treatment of Alzheimers or other medical conditions affecting memory if appropriateness and medical necessity determinations are made in the same manner as those determinations are made for the treatment of any other illness, condition, or disorder covered by the plan contract.
(d)Coverage criteria for FDA-approved treatments described in this section shall not be more restrictive than the FDA-approved indications for those treatments.
(e)Notwithstanding paragraph (3) of subdivision (b), a health insurer that, as a medical benefit, covers nonself-administered treatments approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory shall also include those nonself- administered treatments approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory as an outpatient prescription drug benefit.(f)(e)For purposes of this section, a health insurer shall maintain an expeditious process by which prescribing providers may obtain authorization for a medically necessary treatment approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory, memory shall be considered an exigent circumstance, consistent with the requirements of this article. Section 10123.191.
(g)(f)This section does not apply to vision-only, dental-only, accident-only, specified disease, hospital indemnity, or Medicare supplement insurance policies.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)A health care service plan contract that is issued, amended, or renewed on or after January 1, 2027, shall include coverage for all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimers disease or other related dementia. Medically necessary treatments or medications include, but are not limited to, those that reduce clinical decline.
(b)(1)On and after January 1, 2027, a health care service plan shall not impose step therapy protocols as a prerequisite to authorizing coverage of medically necessary treatments or medications approved by the FDA for the treatment of Alzheimers disease, except as provided in paragraph (3). For purposes of this section, step therapy protocol means a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed.
(2)For purposes of this subdivision, step therapy is prohibited for both self-administered drugs and physician-administered drugs, except as provided in paragraph (3).
(3)If the FDA has approved one or more types of treatment for Alzheimers disease or other medical conditions affecting memory, this section does not require a health care service plan to cover all types of treatment for Alzheimers disease or other medical conditions affecting memory without step therapy, if at least one antiamyloid therapy is covered without step therapy.
(c)This section does not prohibit a health care service plan from applying utilization management, including prior authorization, to determine the medical necessity for treatment of Alzheimers or other medical conditions affecting memory if appropriateness and medical necessity determinations are made in the same manner as those determinations are made for the treatment of any other illness, condition, or disorder covered by the plan contract.
(d)Coverage criteria for FDA-approved treatments described in this section shall not be more restrictive than the FDA-approved indications for those treatments.
(e)Notwithstanding paragraph (3) of subdivision (b), a health care service plan that, as a medical benefit, covers nonself-administered treatments approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory shall also include those nonself-administered treatments approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory as an outpatient prescription drug benefit.
(f)For purposes of this section, a health care service plan shall maintain an expeditious process by which prescribing providers may obtain authorization for a medically necessary treatment approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory, consistent with the requirements of this article.
(g)This section does not apply to the following:
(1)A specialized health care service plan contract that covers only dental or vision benefits or a Medicare supplement contract.
(2)A Medi-Cal managed care plan contract with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14591) of Part 3 of Division 9 of the Welfare and Institutions Code.
SEC. 2.Section 10123.175 is added to the Insurance Code, to read:10123.175.(a)A health insurance policy that is issued, amended, or renewed on or after January 1, 2027, shall include coverage for all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimers disease or other related dementia. Medically necessary treatments or medications include, but are not limited to, those that reduce clinical decline.
(b)(1)On and after January 1, 2027, a health insurer shall not impose step therapy protocols as a prerequisite to authorizing coverage of medically necessary treatments or medications approved by the FDA for the treatment of Alzheimers disease, except as provided in paragraph (3). For purposes of this section, step therapy protocol means a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed.
(2)For purposes of this subdivision, step therapy is prohibited for both self-administered drugs and physician-administered drugs, except as provided in paragraph (3).
(3)If the FDA has approved one or more types of treatment for Alzheimers disease or other medical conditions affecting memory, this section does not require a health insurer to cover all types of treatment for Alzheimers disease or other medical conditions affecting memory without step therapy, if at least one antiamyloid therapy is covered without step therapy.
(c)This section does not prohibit a health insurer from applying utilization management, including prior authorization, to determine the medical necessity for treatment of Alzheimers or other medical conditions affecting memory if appropriateness and medical necessity determinations are made in the same manner as those determinations are made for the treatment of any other illness, condition, or disorder covered by the plan contract.
(d)Coverage criteria for FDA-approved treatments described in this section shall not be more restrictive than the FDA-approved indications for those treatments.
(e)Notwithstanding paragraph (3) of subdivision (b), a health insurer that, as a medical benefit, covers nonself-administered treatments approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory shall also include those nonself- administered treatments approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory as an outpatient prescription drug benefit.
(f)For purposes of this section, a health insurer shall maintain an expeditious process by which prescribing providers may obtain authorization for a medically necessary treatment approved by the FDA for the treatment of Alzheimers disease or other medical conditions affecting memory, consistent with the requirements of this article.
(g)This section does not apply to vision-only, dental-only, accident-only, specified disease, hospital indemnity, or Medicare supplement insurance policies.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
|
Date
|
Status
|
|---|---|
| Sep 27, 2026 | Chaptered by Secretary of State. Chapter 662, Statutes of 2026. |
| Sep 27, 2026 | Approved by the Governor. |
| Aug 30, 2026 | Enrolled and presented to the Governor at 6 p.m. |
| Aug 25, 2026 | Assembly amendments concurred in. (Ayes 40. Noes 0. Page 5740.) Ordered to engrossing and enrolling. |
| Aug 25, 2026 | Assembly amendments concurred in. (Ayes 40. Noes 0.) Ordered to engrossing and enrolling. |
| Aug 24, 2026 | In Senate. Concurrence in Assembly amendments pending. |
| Aug 24, 2026 | Read third time. Passed. (Ayes 77. Noes 0. Page 6373.) Ordered to the Senate. |
| Aug 24, 2026 | Read third time. Passed. Ordered to the Senate. |
| Aug 19, 2026 | Ordered to third reading. |
| Aug 19, 2026 | Read third time and amended. |
| Aug 6, 2026 | Read second time. Ordered to third reading. |
| Aug 5, 2026 | From committee: Do pass. (Ayes 15. Noes 0.) (August 5). |
| Jul 2, 2026 | Read second time and amended. Re-referred to Com. on APPR. |
| Jul 1, 2026 | From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 16. Noes 0.) (June 30). |
| Jun 23, 2026 | June 23 set for first hearing canceled at the request of author. |
| May 26, 2026 | Referred to Com. on HEALTH. |
| May 20, 2026 | In Assembly. Read first time. Held at Desk. |
| May 19, 2026 | Read third time. Passed. (Ayes 38. Noes 0. Page 4341.) Ordered to the Assembly. |
| May 19, 2026 | Read third time. Passed. (Ayes 38. Noes 0.) Ordered to the Assembly. |
| Apr 28, 2026 | Read second time. Ordered to third reading. |
| Apr 27, 2026 | From committee: Do pass. (Ayes 7. Noes 0. Page 4070.) (April 27). |
| Apr 27, 2026 | From committee: Do pass. (Ayes 7. Noes 0.) (April 27). |
| Apr 21, 2026 | Set for hearing April 27. |
| Apr 20, 2026 | Read second time and amended. Re-referred to Com. on APPR. |
| Apr 16, 2026 | From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 9. Noes 0. Page 3901.) (April 15). |
| Apr 16, 2026 | From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 9. Noes 0.) (April 15). |
| Mar 27, 2026 | Set for hearing April 15. |
| Feb 11, 2026 | Referred to Com. on HEALTH. |
| Feb 3, 2026 | From printer. May be acted upon on or after March 5. |
| Feb 2, 2026 | Introduced. Read first time. To Com. on RLS. for assignment. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 25, 2026 | Unfinished Business SB950 Weber Pierson et al. Concurrence | Senate Floor |
Passed |
|
| Aug 24, 2026 | SB 950 Weber Pierson Senate Third Reading By Stefani | Assembly Floor |
Passed |
|
| Aug 5, 2026 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Jun 30, 2026 | Do pass as amended and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
|
| May 19, 2026 | Senate 3rd Reading SB950 Weber Pierson et al. | Senate Floor |
Passed |
|
| Apr 27, 2026 | Do pass | Senate Standing Committee on Appropriations |
Passed |
|
| Apr 15, 2026 | Do pass as amended, but first amend, and re-refer to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| Aids Healthcare Foundation | ** Support | |
| Alliance for Patient Access | ** Support | |
| Alzheimer19s Association | ** Support | |
| Alzheimer19s Greater Los Angeles | ** Support | |
| Alzheimer19s Orange County | ** Support | |
| Alzheimer19s San Diego | ** Support | |
| Alzheimer's Association | ** Support | |
| Alzheimer’s Association | ** Support | |
| Alzheimer’s Association | ** Support | |
| Alzheimer’s Greater Los Angeles | ** Support | |
| Alzheimer’s Orange County | ** Support | |
| Alzheimer’s San Diego | ** Support | |
| American Federation of State, County, and Municipal Employees | ** Support | |
| Association of California Healthcare Districts | ** Support | |
| Association Of California Life & Health Insurance Companies | ** Against | |
| Association of California Life & Health Insurance Companies (ACLHIC) | ** Against | |
| Biocom California | ** Support | |
| California Alliance For Retired Americans | ** Support | |
| California Assisted Living Association | ** Support | |
| California Association Of Health Plans | ** Against | |
| California Black Health Network | ** Support | |
| California Chronic Care Coalition | ** Support | |
| California Coalition on Family Caregiving | ** Support | |
| California Life Sciences | ** Support | |
| California Long Term Care Ombudsman Association | ** Support | |
| California PACE Association | ** Support | |
| Clean Earth 4 Kids | ** Support | |
| Disability Rights California | ** Support | |
| Family Caregiver Alliance | ** Support | |
| LeadingAge California | ** Support | |
| Multipurpose Senior Services Program Site Association | ** Support | |
| Western Center on Law & Poverty, INC. | ** Support |
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-4171 | SB 950 |
UNFINISHED BUSINESS
Bill No: SB 950
Author: Weber Pierson (D), et al.
Amended: 8/19/26
Vote: 21
SENATE HEALTH COMMITTEE: 9-0, 4/15/26
AYES: Weber Pierson, Valladares, Caballero, Durazo, Gonzalez, Grove, Padilla, Rubio, Smallwood-Cuevas
NO VOTE RECORDED: Menjivar, Pérez
SENATE APPROPRIATIONS COMMITTEE: 7-0, 4/27/26
AYES: Cervantes, Seyarto, Cabaldon, Dahle, Grayson, Richardson, Wahab
SENATE FLOOR: 38-0, 5/19/26
AYES: Allen, Alvarado-Gil, Archuleta, Arreguín, Ashby, Becker, Blakespear, Cabaldon, Caballero, Cervantes, Choi, Cortese, Dahle, Durazo, Gonzalez, Grayson, Grove, Jones, Laird, Limón, McGuire, McNerney, Menjivar, Ochoa Bogh, Padilla, Pérez, Reyes, Richardson, Rubio, Seyarto, Smallwood-Cuevas, Stern, Strickland, Umberg, Valladares, Wahab, Weber Pierson, Wiener
NO VOTE RECORDED: Hurtado, Niello
ASSEMBLY FLOOR: Passed, 8/24/26
SUBJECT: Health care coverage: dementia
SOURCE: Alzheimer’s Association
DIGEST:
This bill requires health plans and insurers to cover all medically necessary treatments or medications, as determined by a health care provider, that are approved by the federal Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease or other medical conditions affecting memory. Prohibits health plans and insurers from imposing step therapy protocols when one or more medications are approved by the FDA, unless a plan or insurer has covered at least one anti-amyloid therapy without step therapy.
Assembly Amendments delete a provision that indicates that coverage for all medically necessary treatment or medications does not require a plan or insurer to cover more than one pharmaceutically equivalent drug product if the FDA has approved more than one medication or treatment that is pharmaceutically equivalent. An additional amendment replaces the terms “related dementia” with “medical conditions affecting memory.”
ANALYSIS:
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act) and the California Department of Insurance (CDI) to regulate health insurers under the Insurance Code. [Health and Safety Code (HSC) §1340, et seq. and Insurance Code (INS) §106, et seq.]
- Permits health plans and insurers to require step therapy and prior authorization and defines step therapy as a type of protocol that specifies the sequence in which different prescription drugs for a given medical condition that are medically appropriate for a particular patient are to be prescribed. Includes utilization review organizations that perform utilization review or utilization management functions. [HSC §1342.71 and §1367.206, Title 28 California Code of Regulations (CCR) §1300.67.205, and INS §10123.193 and §10123.201]
- Requires a health plan contract that provides coverage for outpatient prescription drugs to cover medically necessary prescription drugs, including nonformulary drugs determined to be medically necessary consistent with the Knox-Keene Act. Excludes specified drugs such as drugs for cosmetic purposes and indicates drugs for mental performance are not excluded when they are used to treat diagnosed mental illness or medical conditions affecting memory, including, but not limited to treatment of the conditions or symptoms of dementia or Alzheimer’s disease. [HSC §1342.71, Title 28, CCR §1300.67.24 and INS §10123.193]
This bill:
- Requires a health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2027, to include coverage for all medically necessary treatments or medications, as determined by a health care provider, that are approved by the FDA for the treatment of Alzheimer’s disease or other medical conditions affecting memory. Indicates medically necessary treatments or medications include, but are not limited to, those that reduce clinical decline.
- Indicates medically necessary treatments or medications include those administered through a medical benefit, an outpatient prescription drug benefit to the extent the plan contract or policy covers outpatient prescription drugs, or both.
- Prohibits a health plan or health insurer from imposing step therapy protocols as a prerequisite to authorizing coverage of medically necessary treatments or medications approved by the FDA for the treatment of Alzheimer’s disease, except as provided in 5) below. Prohibits step therapy for both self-administered drugs and physician-administered drugs, except as provided in 5) below.
- Permits a health plan or health insurer to cover only one anti-amyloid therapy (disease modifying medication) without step therapy if the FDA has approved one or more types of treatment for Alzheimer’s disease or other medical conditions affecting memory.
- Permits a health plan or insurer to apply utilization management, including prior authorization, to determine medical necessity for the treatment of Alzheimer’s or other medical conditions affecting memory, if appropriateness and medical necessity determinations are made in the same manner as treatment of any other illness, condition, or disorder covered by the plan contract or insurance policy.
- Prohibits coverage criteria for FDA-approved treatments from being more restrictive than the FDA-approved indications for those treatments.
- Requires health plan and insurer authorization to be considered an exigent circumstance, consistent with existing law.
- Exempts a specialized health plan or insurer that covers only dental, vision, or Medicare supplement contracts or policies, Medi-Cal managed care plan contracts with Department of Health Care Services, as specified, accident-only, specified disease, or hospital indemnity policies.
Comments
According to the author of this bill:
Alzheimer's disease, while often thought of as a condition of aging, reflects broader disparities in our public health system. Californian women, lower-income Californians, and Californians of color face disproportionately elevated risks, higher diagnosis rates, and poorer outcomes once living with the disease. This devastating diagnosis is life- and community-changing. As Alzheimer’s progresses, individuals lose independence and the memories that connect them to their loved ones. Families often sacrifice their livelihoods to become caregivers while navigating a complex health system. During one of the most difficult times in their lives, California cannot allow barriers to delay or prevent access to appropriate treatment. Today, FDA-approved therapies offer new hope by slowing the progression of Alzheimer’s disease in its early stages. Removing the plaque responsible for progression can preserve precious time, memories, and quality of life. But, because they are only effective early in the disease, any delays can take away the opportunity to receive this treatment altogether. As a state, we must ensure timely access to these treatments and alleviate pressure from our families and healthcare system. Families deserve more time and support when navigating Alzheimer’s.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Assembly Appropriations Committee DMHC and CDI anticipate minor and absorbable costs.
The California Public Employees Retirement System anticipates no costs.
SUPPORT: (Verified 8/20/26)
Alzheimer’s Association (source)
AIDS Healthcare Foundation
Alliance for Patient Access
Alzheimer’s Greater Los Angeles
Alzheimer’s Orange County
Alzheimer’s San Diego
American Federation of State, County, and Municipal Employees
Association of California Healthcare Districts
Biocom California
California Alliance for Retired Americans
California Assisted Living Association
California Black Health Network
California Chronic Care Coalition
California Coalition on Family Caregiving
California Life Sciences
California Long Term Care Ombudsman Association
California PACE Association
Clean Earth 4 Kids
Disability Rights California
Family Caregiver Alliance
LeadingAge California
Multipurpose Senior Services Program Site Association
Western Center on Law & Poverty, Inc.
Two individuals
OPPOSITION: (Verified 8/20/26)
Association of California Life & Health Insurance Companies
California Association of Health Plans
One individual
ARGUMENTS IN SUPPORT: This bill’s sponsor, the Alzheimer’s Association, writes that “this legislation expedites access for monoclonal antibody therapies that target amyloid plaque buildup in the brain to reduce cognitive decline. These are among the first disease modifying treatments to become available for Alzheimer’s disease. The advent of these treatments along with blood-based biomarker testing and new research on lifestyle interventions’ efficacy staving off cognitive decline have encouraged early detection and diagnosis of Alzheimer’s disease. Perspectives have changed because these developments provide proactive measures to manage cognitive decline for individuals contending with a diagnosis. Presently, these therapies are only available for those in the early stage of Alzheimer’s disease, making access crucial.”
ARGUMENTS IN OPPOSITION: The California Association of Health Plans (CAHP) and the Association of California Life and Health Insurance Companies (ACLHIC) indicate that the demonstrated effectiveness of anti-amyloids has not been clearly substantiated, and they reference CHBRP statements that there is not enough research to determine whether amyloid plaque reduction improves health outcomes and that the small effect sizes did not meet the threshold for minimum clinically important differences. They are also concerned that this bill will accelerate utilization of these drugs before their value is proven and the infrastructure for treatment is available. Regarding the step therapy requirement, CAHP and ACLHIC are concerned that it further grants immediate access to a drug that has not been proven to improve health outcomes, which is a concern because an individual course of treatment is between $26,500 - $32,000.
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
8/24/26 16:06:45
**** END ****
SENATE THIRD READING
STR Bill Id:SB 950
Author:(Weber Pierson)
As Amended Ver:August 19, 2026
Majority vote
SUMMARY
Requires a health plan and insurer to cover all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease or other medical conditions affecting memory.
Major Provisions
COMMENTS
Alzheimer's disease is a progressive, irreversible neurologic condition that damages and destroys neurons in the brain. As the disease progresses, memory, language, and cognitive processing challenges are often the first symptoms to emerge. Patients with Alzheimer's disease may live up to 10 years or longer after receiving a diagnosis, spending roughly 40% of that time in the more severe stages of disease, during which they need help with activities of daily living. Early-onset Alzheimer's disease is a form of Alzheimer’s dementia that develops before the age of 65 years and is often associated with a faster cognitive decline. As patients lose the ability to drive, work, and care for themselves, support from others becomes necessary. In 2024, an estimated 19.2 billion hours of assistance was provided for people with Alzheimer's disease by unpaid caregivers. There is no cure or treatment to reverse Alzheimer's disease, and it is eventually fatal. In 2022, an estimated 17,363 people died from Alzheimer's disease in California. Alzheimer’s disease is distinguished from other forms of dementia and cognitive impairment by two biomarkers that accumulate in the brain: an abnormal form of tau protein and beta-amyloid protein fragments. Brain inflammation, atrophy, and reduced glucose metabolism and uptake by the brain cells are also pathological features of the disease.
Medications for Alzheimer's. Medication treatments for Alzheimer's disease include medications that treat symptoms of the disease, which treat symptoms of dementia without altering beta-amyloid accumulation and can be used at any stage of the disease. There are also disease-modifying medications that aim to alter the rate of disease progression by slowing and reversing beta-amyloid accumulation in the brain. Barriers to receiving a diagnosis for Alzheimer's disease and accessing disease-modifying medications are substantial and may be attributed to the limited supply of treating clinicians. According to the California Health Benefits Review Program (CHBRP) currently, disease-modifying medications are only available for patients who meet certain clinical criteria. Eligibility to receive disease-modifying medications is narrow, requires special testing, and may only be available in specialized facilities.
CHBRP. CHBRP was created in response to AB 1996 (Thomson), Chapter 795, Statutes of 2002, which requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on essential health benefits (EHBs), and legislation that impacts health insurance benefit designs, cost-sharing, premiums, and other health insurance topics to CHBRP's purview. CHBRP reviewed this bill and included the following impact estimates in their analysis:
- Increased premiums and consumer costs. CHBRP estimates that the introduced version of this bill would result in 66 additional enrollees receiving medications to treat symptoms and 23 additional enrollees receiving disease-modifying medications. Total annual premiums would increase by $660,000, or up to $0.03 per member per month. Cost-sharing for enrollees who are new users of these medications would increase between $1,310 and $1,990 annually. CHBRP notes that amendments taken in the Senate would likely result in fewer enrollees newly using some medications. As a result, fiscal impacts would be slightly lower than projected in CHBRP's initial analysis.
- Medical effectiveness. Medications that treat symptoms of Alzheimer's disease demonstrate generally small and inconsistent effects across medications, severity of disease, and outcomes; strength of evidence varies. Disease-modifying medications demonstrate strong, consistent effects on amyloid biomarkers, with substantial reductions in amyloid burden and high rates of amyloid clearance across studies. There is some evidence that these therapies slow cognitive decline, functional decline, and combined measures of cognition and function; however, effect sizes were generally modest, and most findings did not meet thresholds for clinical meaningfulness. While there is some evidence disease-modifying medications are associated with an increased risk of harms, they are often asymptomatic but can occasionally result in serious harm.
- Limited public health impacts. CHBRP projects no measurable public health impact at the population level due to the small estimated increase in utilization in the small population that would be covered by this bill and eligible for the medications. However, this bill would likely yield some health and quality-of-life improvements, such as slowing the decline of cognitive function, functional ability, and global assessment after 18 months of treatment among the 23 additional enrollees who would newly have access to and use disease-modifying medications.
According to the Author
Alzheimer's disease, while often thought of as a condition of aging, reflects broader disparities in our public health system. Californian women, lower-income Californians, and Californians of color face disproportionately elevated risks, higher diagnosis rates, and poorer outcomes once living with the disease. The author states that this devastating diagnosis is life- and community-changing. The author continues that as Alzheimer's progresses; individuals lose independence and the memories that connect them to their loved ones. The author notes that families often sacrifice their livelihoods to become caregivers while navigating a complex health system. The author states that during one of the most difficult times in their lives, California cannot allow barriers to delay or prevent access to appropriate treatment. The author continues that FDA-approved therapies offer new hope by slowing the progression of Alzheimer's disease in its early stages. The author states that removing the plaque responsible for the progression can preserve precious time, memories, and quality of life. But, the author argues that because they are only effective early in the disease, any delays can take away the opportunity to receive this treatment altogether. The author concludes that as a state, we must ensure timely access to these treatments and alleviate pressure from our families and healthcare system. Families deserve more time and support when navigating Alzheimer's.
Arguments in Support
The Alzheimer's Association is sponsoring this bill, stating that it expedites access for monoclonal antibody therapies that target amyloid plaque buildup in the brain to reduce cognitive decline. The Alzheimer's Association continues that these are among the first disease modifying treatments to become available for Alzheimer's disease, and alongside blood-based biomarker testing and new research have encouraged early detection and diagnosis of Alzheimer's disease. The Alzheimer’s Association argues that this legislation provides needed clarity in state law to ensure uninterrupted coverage for these new developments, so individuals do not unnecessarily exit their eligibility window and advance in the disease progression, which can involve higher costs and levels of care.
Arguments in Opposition
The California Association of Health Plans (CAHP) and the Association of California Life & Health Insurance Companies (ACLHIC) write in opposition stating that even though this bill permits plans/insurers to apply utilization management like prior authorization, the bill requires that all products to treat Alzheimer's be included on formularies, forcing plans to adjust their current coverage, impacting health care affordability. CAHP and ACLHIC continue that this bill prevents plans from updating their policies as new data emerges and from designing policies that are both affordable and appropriate for a specific diagnosis. CAHP and ACLHIC cite the CHBRP analysis, which noted there is "some evidence that disease-modifying medications are effective at slowing cognitive decline" but adds that "these effects generally fell below minimum clinically important difference thresholds." CAHP and ACLHIC are concerned that due to the intensive treatment requirements, potential of severe side effects, and limited amount of providers who have experience prescribing and providing this treatment, this bill will accelerate utilization of these drugs before their value is proven and the infrastructure for treatment is available. Finally, CAHP and ACLHIC are concerned with the recent amendment that requires anti-amyloids and other Alzheimer's drugs to be treated as an exigent circumstance. CAHP and ACLHIC conclude that 24-hour review is an incredibly short timeline for an entire class of drugs, specifically ones (like anti-amyloids) that are new to the market and required to be used under strict guidelines and supervision.
FISCAL COMMENTS
According to the Assembly Appropriations Committee, the Department of Managed Health Care and the Department of Insurance anticipate minor and absorbable costs. The California Public Employees Retirement System anticipates no costs.
VOTES
SENATE FLOOR: 38-0-2
YES: Allen, Alvarado-Gil, Archuleta, Arreguín, Ashby, Becker, Blakespear, Cabaldon, Caballero, Cervantes, Choi, Cortese, Dahle, Durazo, Gonzalez, Grayson, Grove, Jones, Laird, Limón, McGuire, McNerney, Menjivar, Ochoa Bogh, Padilla, Pérez, Reyes, Richardson, Rubio, Seyarto, Smallwood-Cuevas, Stern, Strickland, Umberg, Valladares, Wahab, Weber Pierson, Wiener
ABS, ABST OR NV: Hurtado, Niello
ASM HEALTH: 16-0-0
YES: Bonta, Sanchez, Addis, Aguiar-Curry, Ahrens, Caloza, Carrillo, Jeff Gonzalez, Mark González, Johnson, Patel, Patterson, Celeste Rodriguez, Schiavo, Sharp-Collins, Stefani
ASM APPROPRIATIONS: 15-0-0
YES: Wicks, Hoover, Arambula, Calderon, Caloza, Dixon, Fong, Mark González, Krell, Pacheco, Pellerin, Sharp-Collins, Solache, Ta, Tangipa
UPDATED
VERSION: August 19, 2026
CONSULTANT: Riana King / HEALTH / (916) 319-2097 FN: 0003828
SENATE THIRD READING
STR Bill Id:SB 950
Author:(Weber Pierson)
As Amended Ver:July 2, 2026
Majority vote
SUMMARY
Requires a health plan and insurer to cover all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimer's disease or other related dementia.
Major Provisions
COMMENTS
Alzheimer's disease is a progressive, irreversible neurologic condition that damages and destroys neurons in the brain. As the disease progresses, memory, language, and cognitive processing challenges are often the first symptoms to emerge. Patients with Alzheimer's disease may live up to 10 years or longer after receiving a diagnosis, spending roughly 40% of that time in the more severe stages of disease, during which they need help with activities of daily living. Early-onset Alzheimer's disease is a form of Alzheimer's dementia that develops before the age of 65 years and is often associated with a faster cognitive decline. As patients lose the ability to drive, work, and care for themselves, support from others becomes necessary. In 2024, an estimated 19.2 billion hours of assistance was provided for people with Alzheimer's disease by unpaid caregivers. There is no cure or treatment to reverse Alzheimer's disease, and it is eventually fatal. In 2022, an estimated 17,363 people died from Alzheimer's disease in California. Alzheimer's disease is distinguished from other forms of dementia and cognitive impairment by two biomarkers that accumulate in the brain: an abnormal form of tau protein and beta-amyloid protein fragments. Brain inflammation, atrophy, and reduced glucose metabolism and uptake by the brain cells are also pathological features of the disease.
Medications for Alzheimer's. Medication treatments for Alzheimer's disease include medications that treat symptoms of the disease, which treat symptoms of dementia without altering beta-amyloid accumulation and can be used at any stage of the disease. There are also disease-modifying medications that aim to alter the rate of disease progression by slowing and reversing beta-amyloid accumulation in the brain. Barriers to receiving a diagnosis for Alzheimer's disease and accessing disease-modifying medications are substantial and may be attributed to the limited supply of treating clinicians. According to the California Health Benefits Review Program (CHBRP) currently, disease-modifying medications are only available for patients who meet certain clinical criteria. Eligibility to receive disease-modifying medications is narrow, requires special testing, and may only be available in specialized facilities.
CHBRP. CHBRP was created in response to AB 1996 (Thomson), Chapter 795, Statutes of 2002, which requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on essential health benefits (EHBs), and legislation that impacts health insurance benefit designs, cost-sharing, premiums, and other health insurance topics to CHBRP's purview. CHBRP reviewed this bill and included the following impact estimates in their analysis:
- Increased premiums and consumer costs. CHBRP estimates that the introduced version of this bill would result in 66 additional enrollees receiving medications to treat symptoms and 23 additional enrollees receiving disease-modifying medications. Total annual premiums would increase by $660,000, or up to $0.03 per member per month. Cost-sharing for enrollees who are new users of these medications would increase between $1,310 and $1,990 annually. CHBRP notes that amendments taken in the Senate would likely result in fewer enrollees newly using some medications. As a result, fiscal impacts would be slightly lower than projected in CHBRP's initial analysis.
- Medical effectiveness. Medications that treat symptoms of Alzheimer's disease demonstrate generally small and inconsistent effects across medications, severity of disease, and outcomes; strength of evidence varies. Disease-modifying medications demonstrate strong, consistent effects on amyloid biomarkers, with substantial reductions in amyloid burden and high rates of amyloid clearance across studies. There is some evidence that these therapies slow cognitive decline, functional decline, and combined measures of cognition and function; however, effect sizes were generally modest, and most findings did not meet thresholds for clinical meaningfulness. While there is some evidence disease-modifying medications are associated with an increased risk of harms, they are often asymptomatic but can occasionally result in serious harm.
- Limited public health impacts. CHBRP projects no measurable public health impact at the population level due to the small estimated increase in utilization in the small population that would be covered by this bill and eligible for the medications. However, this bill would likely yield some health and quality-of-life improvements, such as slowing the decline of cognitive function, functional ability, and global assessment after 18 months of treatment among the 23 additional enrollees who would newly have access to and use disease-modifying medications.
According to the Author
Alzheimer's disease, while often thought of as a condition of aging, reflects broader disparities in our public health system. Californian women, lower-income Californians, and Californians of color face disproportionately elevated risks, higher diagnosis rates, and poorer outcomes once living with the disease. The author states that this devastating diagnosis is life- and community-changing. The author continues that as Alzheimer's progresses; individuals lose independence and the memories that connect them to their loved ones. The author notes that families often sacrifice their livelihoods to become caregivers while navigating a complex health system. The author states that during one of the most difficult times in their lives, California cannot allow barriers to delay or prevent access to appropriate treatment. The author continues that FDA-approved therapies offer new hope by slowing the progression of Alzheimer's disease in its early stages. The author states that removing the plaque responsible for the progression can preserve precious time, memories, and quality of life. But, the author argues that because they are only effective early in the disease, any delays can take away the opportunity to receive this treatment altogether. The author concludes that as a state, we must ensure timely access to these treatments and alleviate pressure from our families and healthcare system. Families deserve more time and support when navigating Alzheimer's.
Arguments in Support
The Alzheimer's Association is sponsoring this bill, stating that it expedites access for monoclonal antibody therapies that target amyloid plaque buildup in the brain to reduce cognitive decline. The Alzheimer's Association continues that these are among the first disease modifying treatments to become available for Alzheimer's disease, and alongside blood-based biomarker testing and new research have encouraged early detection and diagnosis of Alzheimer's disease. The Alzheimer's Association argues that this legislation provides needed clarity in state law to ensure uninterrupted coverage for these new developments, so individuals do not unnecessarily exit their eligibility window and advance in the disease progression, which can involve higher costs and levels of care.
Arguments in Opposition
The California Association of Health Plans (CAHP) and the Association of California Life & Health Insurance Companies (ACLHIC) write in opposition stating that even though this bill permits plans/insurers to apply utilization management like prior authorization, the bill requires that all products to treat Alzheimer's be included on formularies, forcing plans to adjust their current coverage, impacting health care affordability. CAHP and ACLHIC continue that this bill prevents plans from updating their policies as new data emerges and from designing policies that are both affordable and appropriate for a specific diagnosis. CAHP and ACLHIC cite the CHBRP analysis, which noted there is "some evidence that disease-modifying medications are effective at slowing cognitive decline" but adds that "these effects generally fell below minimum clinically important difference thresholds." CAHP and ACLHIC are concerned that due to the intensive treatment requirements, potential of severe side effects, and limited amount of providers who have experience prescribing and providing this treatment, this bill will accelerate utilization of these drugs before their value is proven and the infrastructure for treatment is available. Finally, CAHP and ACLHIC are concerned with the recent amendment that requires anti-amyloids and other Alzheimer's drugs to be treated as an exigent circumstance. CAHP and ACLHIC conclude that 24-hour review is an incredibly short timeline for an entire class of drugs, specifically ones (like anti-amyloids) that are new to the market and required to be used under strict guidelines and supervision.
FISCAL COMMENTS
According to the Assembly Appropriations Committee, the Department of Managed Health Care and the Department of Insurance anticipate minor and absorbable costs. The California Public Employees Retirement System anticipates no costs.
VOTES
SENATE FLOOR: 38-0-2
YES: Allen, Alvarado-Gil, Archuleta, Arreguín, Ashby, Becker, Blakespear, Cabaldon, Caballero, Cervantes, Choi, Cortese, Dahle, Durazo, Gonzalez, Grayson, Grove, Jones, Laird, Limón, McGuire, McNerney, Menjivar, Ochoa Bogh, Padilla, Pérez, Reyes, Richardson, Rubio, Seyarto, Smallwood-Cuevas, Stern, Strickland, Umberg, Valladares, Wahab, Weber Pierson, Wiener
ABS, ABST OR NV: Hurtado, Niello
ASM HEALTH: 16-0-0
YES: Bonta, Sanchez, Addis, Aguiar-Curry, Ahrens, Caloza, Carrillo, Jeff Gonzalez, Mark González, Johnson, Patel, Patterson, Celeste Rodriguez, Schiavo, Sharp-Collins, Stefani
ASM APPROPRIATIONS: 15-0-0
YES: Wicks, Hoover, Arambula, Calderon, Caloza, Dixon, Fong, Mark González, Krell, Pacheco, Pellerin, Sharp-Collins, Solache, Ta, Tangipa
UPDATED
VERSION: July 2, 2026
CONSULTANT: Riana King / HEALTH / (916) 319-2097 FN: 0003345
Date of Hearing: August 5, 2026
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Buffy Wicks, Chair
SBPCA Bill Id:SB 950
Author:(Weber Pierson) – As Amended Ver:July 2, 2026
Policy Committee: | Health | Vote: | 16 - 0 |
|
| ||
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill requires a health plan and health insurer to cover all medically necessary treatments or medications, as determined by a health care provider and approved by the U.S. Food and Drug Administration (FDA), without step therapy, for the treatment of Alzheimer’s disease or other related dementia.
More specifically, this bill:
- Requires a health plan and health insurer (collectively, health plan) cover all medically necessary treatments or medications, as determined by a health care provider, that are approved by the FDA for the treatment of Alzheimer’s disease or other related dementia.
- Defines medically necessary treatments or medications to include, but not be limited to, those that reduce clinical decline.
- Includes medications administered through a medical benefit and an outpatient prescription drug benefit, to the extent the health plan or contract covers outpatient prescription drugs, in the definition of medically necessary treatments in item 1, above.
- Prohibits a health plan and insurer from imposing step therapy protocols as a prerequisite to authorizing coverage pursuant to item 1, above.
- Exempts a health plan from covering all types of treatment for Alzheimer’s disease or other medical conditions affecting memory without step therapy if at least one antiamyloid therapy is covered without step therapy, as specified.
- Allows a health plan to apply utilization management, including prior authorization, to determine the medical necessity for treatment of Alzheimer’s or other medical conditions affecting memory if such determinations are made in the same manner as for the treatment of any other illness, condition, or disorder covered by the plan or insurer.
- Requires a health plan’s coverage criteria for FDA-approved treatments under this bill to not be more restrictive than FDA-approved indications for those treatments.
- Requires a health plan consider authorization for a medically necessary treatment approved by the FDA for the treatment of Alzheimer’s disease or other medical conditions affecting memory an exigent circumstance requiring a 24-hour review timeline.
- Exempts Medicare supplements, Medi-Cal managed care plans, and specialized health care service plans.
FISCAL EFFECT:
The Department of Managed Health Care and the Department of Insurance anticipate minor and absorbable costs.
The California Public Employees Retirement System anticipates no costs.
COMMENTS:
- Purpose. This bill is sponsored by the Alzheimer’s Association. The author intends this bill to reduce delays to appropriate treatment for Alzheimer’s disease and similar conditions. According to the author:
California cannot allow barriers to delay or prevent access to appropriate treatment.
Today, FDA-approved therapies offer new hope by slowing the progression of Alzheimer’s disease in its early stages. Removing the plaque responsible for the progression can preserve precious time, memories, and quality of life. But, because they are only effective early in the disease, any delays can take away the opportunity to receive this treatment altogether.
- Background. The California Health Benefits Review Program (CHBRP) reports medications that treat symptoms of Alzheimer’s disease demonstrate generally small and inconsistent effects across medications, severity of disease, and outcomes, and that the strength of the evidence varies. Disease-modifying medications demonstrate strong, consistent effects on amyloid biomarkers, with some evidence such therapies slow cognitive decline and functional decline; however, effect sizes were generally modest, and most findings did not meet thresholds for clinical meaningfulness.
CHBRP estimated the introduced version of this bill would result in 66 additional enrollees receiving medications to treat symptoms and 23 additional enrollees receiving disease-modifying medications. Total annual premiums across the state would increase by $7.9 million, or $660,000 per month, or $0.03 per member, per month. Cost sharing for enrollees who are new users of these medications would increase between $1,310 and $1,990 annually. CHBRP notes that amendments taken after CHBRP initiated its analysis would likely result in fewer enrollees newly using some medications and a slightly smaller fiscal effect than projected in analysis.
- Opposition. The California Association of Health Plans (CAHP) and the Association of California Life & Health Insurance Companies (ACLHIC) write in opposition, stating this bill prevents plans from updating their policies as new data emerges and from designing policies that are both affordable and appropriate for a specific diagnosis. CAHP and ACLHIC note that the due to the intensive treatment requirements, potential of severe side effects, and limited amount of providers who have experience prescribing and providing this treatment, this bill will accelerate utilization of these drugs before their value is proven and the infrastructure for treatment is available. Further, CAHP and ACLHIC are concerned with the recent amendment that requires anti-amyloids and other Alzheimer’s drugs to be treated as an exigent circumstance, as 24-hour review is a short timeline for an entire class of drugs, specifically drugs like anti-amyloids that are new to the market and must be used under strict guidelines and supervision.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: June 30, 2026
ASSEMBLY COMMITTEE ON HEALTH
Mia Bonta, Chair
SBPCA Bill Id:SB 950
Author:(Weber Pierson) – As Amended Ver:April 20, 2026
SENATE VOTE: 38-0
SUBJECT: Health care coverage: dementia.
SUMMARY: Requires a health plan and insurer to cover all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease or other related dementia. Specifically, this bill:
- Requires a health plan and health insurer to cover all medically necessary treatments or medications, as determined by a health care provider, approved by the FDA for the treatment of Alzheimer’s disease or other related dementia. Defines medically necessary treatments or medications to include, but not be limited to, those that reduce clinical decline.
- Includes medications administered through a medical benefit, an outpatient prescription drug benefit to the extent the health care service plan contract covers outpatient prescription drugs, or both in the definition of medically necessary treatments in 1) above.
- States that coverage for all medically necessary treatment or medications pursuant to paragraph 1) above does not require a health care service plan contract to cover drugs or treatments that are pharmaceutically equivalent drug products if the FDA approves more than one medication or treatment that are pharmaceutically equivalent drug products, unless otherwise required by law.
- Prohibits a health plan and insurer from imposing step therapy protocols as a prerequisite to authorizing coverage of medically necessary treatments or medications approved by the FDA for the treatment of Alzheimer’s disease. Defines “step therapy protocol” as a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed. Specifies that step therapy is prohibited for both self-administered drugs and physician-administered drugs.
- Exempts plans and insurers from covering all types of treatment for Alzheimer’s disease or other medical conditions affecting memory without step therapy if at least one antiamyloid therapy is covered without step therapy, as specified.
- Permits a health plan and insurer to apply utilization management (UM), including prior authorization (PA), to determine the medical necessity for treatment of Alzheimer’s or other medical conditions affecting memory if appropriateness and medical necessity determinations are made in the same manner as those determinations are made for the treatment of any other illness, condition, or disorder covered by the plan or insurer.
- Requires coverage criteria for FDA-approved treatments under this bill to not be more restrictive than FDA-approved indications for those treatments.
- Requires authorization for a medically necessary treatment approved by the FDA for the treatment of Alzheimer’s disease or other medical conditions affecting memory to be considered an exigent circumstance (requiring a 24-hour review timeline), consistent with requirements under existing law.
- Exempts Medicare supplements, Medi-Cal managed care plans, specialized health care service plans that cover only dental or vision benefits, vision-only, dental-only, accident-only, specified disease, and hospital indemnity insurers from this bill.
EXISTING LAW:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 and California Department of Insurance (CDI) to regulate health insurers. [Health and Safety Code (HSC) § 1340, et seq., and Insurance Code (INS) § 106, et seq.]
- Establishes California's essential health benefits (EHBs) benchmark under the Patient Protection and Affordable Care Act (ACA) as the Kaiser Small Group Health Maintenance Organization, establishes existing California health insurance mandates, and the 10 ACA mandated benefits, including prescription drug coverage. [HSC § 1367.005 and INS § 10112.27]
- Defines “basic health care services” as all of the following:
- Physician services, including consultation and referral;
- Hospital inpatient services and ambulatory care services;
- Diagnostic laboratory and therapeutic radiologic services;
- Home health services;
- Preventive health services;
- Emergency health care services, including ambulance and ambulance transport services and out-of-area coverage. Basic health care services includes ambulance and ambulance transport services provided through the 911 emergency response system; and,
- Hospice care, as specified. [HSC § 1345 and INS § 10112.281]
- Permits health plans and insurers to require step therapy and prior authorization and defines step therapy as a type of protocol that specifies the sequence in which different prescription drugs for a given medical condition that are medically appropriate for a particular patient are to be prescribed. Includes utilization review organizations that perform utilization review (UR) or UM functions. [HSC § 1342.71 and § 1367.206, Title 28 California Code of Regulations (CCR) § 1300.67.205, and INS § 10123.193 and § 10123.201]
- Requires health plans and disability insurers and any contracted entity that performs UR or UM functions, prospectively, retrospectively, or concurrently, based on medical necessity requests to comply with specified requirements. [HSC § 1367.01 and INS § 10123.135]
- Requires decisions to approve, modify, or deny, based on medical necessity, requests by providers prior to, or concurrent with the provision of health care services to be made in a timely fashion that does not to exceed five business days from the health plan or health insurer’s receipt of the information reasonably necessary and requested by the plan to make the determination. Requires, in cases where the review is retrospective, the decision to be communicated to the individual who received services, or to the individual’s designee, within 30 days of the receipt of information that is reasonably necessary to make this determination, and be communicated to the provider in a manner that is consistent with current law. [HSC § 1367.01 and INS § 10123.135]
- Authorizes a health care provider or prescribing provider, enrollee, insured, or their designee or guardian to appeal a denial of an exception request for coverage of a nonformulary drug, prior authorization request, or step therapy exception request consistent with the plan’s or insurer’s current UM process. [HSC § 1367.206 and INS § 10123.201]
- Prohibits a health plan or insurer from subjecting antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including PrEP or PEP, to PA or step therapy. Permits a health plan or insurer not to cover all of the therapeutically equivalent versions without PA or step therapy, if at least one therapeutically equivalent version is covered without PA or step therapy, if the FDA has approved one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV. Limits coverage to a 60-day supply to a single patient once every two years, unless the pharmacist has been directed otherwise by a prescriber. [HSC § 1342.74 and INS § 10123.1933]
FISCAL EFFECT: According to the Senate Appropriations Committee, DMHC anticipates minor and absorbable costs for state administration (Managed Care Fund). CDI estimates costs of $11,000 in 2026-27 and $23,000 in 2027-28 for state administration (Insurance Fund).
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, Alzheimer's disease, while often thought of as a condition of aging, reflects broader disparities in our public health system. Californian women, lower-income Californians, and Californians of color face disproportionately elevated risks, higher diagnosis rates, and poorer outcomes once living with the disease. The author states that this devastating diagnosis is life- and community-changing. The author continues that as Alzheimer’s progresses; individuals lose independence and the memories that connect them to their loved ones. The author notes that families often sacrifice their livelihoods to become caregivers while navigating a complex health system. The author states that during one of the most difficult times in their lives, California cannot allow barriers to delay or prevent access to appropriate treatment. The author continues that FDA-approved therapies offer new hope by slowing the progression of Alzheimer’s disease in its early stages. The author states that removing the plaque responsible for the progression can preserve precious time, memories, and quality of life. But, the author argues that because they are only effective early in the disease, any delays can take away the opportunity to receive this treatment altogether. The author concludes that as a state, we must ensure timely access to these treatments and alleviate pressure from our families and healthcare system. Families deserve more time and support when navigating Alzheimer’s.
- BACKGROUND. Alzheimer’s disease is a progressive, irreversible neurologic condition that damages and destroys neurons in the brain. As the disease progresses, memory, language, and cognitive processing challenges are often the first symptoms to emerge. Patients with Alzheimer’s disease may live up to 10 years or longer after receiving a diagnosis, spending roughly 40% of that time in the more severe stages of disease, during which they need help with activities of daily living. Early-onset Alzheimer's disease is a form of Alzheimer’s dementia that develops before the age of 65 years and is often associated with a faster cognitive decline. As patients lose the ability to drive, work, and care for themselves, support from others becomes necessary. In 2024, an estimated 19.2 billion hours of assistance was provided for people with Alzheimer's disease by unpaid caregivers. There is no cure or treatment to reverse Alzheimer's disease, and it is eventually fatal. In 2022, an estimated 17,363 people died from Alzheimer’s disease in California. Alzheimer’s disease is distinguished from other forms of dementia and cognitive impairment by two biomarkers that accumulate in the brain: an abnormal form of tau protein and beta-amyloid protein fragments. Brain inflammation, atrophy, and reduced glucose metabolism and uptake by the brain cells are also pathological features of the disease.
- Medications for Alzheimer’s. Medication treatments for Alzheimer’s disease include medications that treat symptoms of the disease, which treat symptoms of dementia without altering beta-amyloid accumulation and can be used at any stage of the disease. There are also disease-modifying medications that aim to alter the rate of disease progression by slowing and reversing beta-amyloid accumulation in the brain. Barriers to receiving a diagnosis for Alzheimer's disease and accessing disease-modifying medications are substantial and may be attributed to the limited supply of treating clinicians. According to the California Health Benefits Review Program (CHBRP) currently, disease-modifying medications are only available for patients who meet certain clinical criteria. Eligibility to receive disease-modifying medications is narrow, requires special testing, and may only be available in specialized facilities.
- CHBRP. CHBRP was created in response to AB 1996 (Thomson), Chapter 795, Statutes of 2002, which requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost-sharing, premiums, and other health insurance topics to CHBRP’s purview. CHBRP reviewed this bill and included the following impact estimates in their analysis:
- Increased premiums and consumer costs. CHBRP estimates that the introduced version of this bill would result in 66 additional enrollees receiving medications to treat symptoms and 23 additional enrollees receiving disease-modifying medications. Total annual premiums would increase by $660,000, or up to $0.03 per member per month. Cost-sharing for enrollees who are new users of these medications would increase between $1,310 and $1,990 annually. CHBRP notes that amendments taken in the Senate would likely result in fewer enrollees newly using some medications. As a result, fiscal impacts would be slightly lower than projected in CHBRP’s initial analysis.
- Medical effectiveness. Medications that treat symptoms of Alzheimer’s disease demonstrate generally small and inconsistent effects across medications, severity of disease, and outcomes; strength of evidence varies. Disease-modifying medications demonstrate strong, consistent effects on amyloid biomarkers, with substantial reductions in amyloid burden and high rates of amyloid clearance across studies. There is some evidence that these therapies slow cognitive decline, functional decline, and combined measures of cognition and function; however, effect sizes were generally modest, and most findings did not meet thresholds for clinical meaningfulness. While there is some evidence disease-modifying medications are associated with an increased risk of harms, they are often asymptomatic but can occasionally result in serious harm.
- Limited public health impacts. CHBRP projects no measurable public health impact at the population level due to the small estimated increase in utilization in the small population that would be covered by this bill and eligible for the medications. However, this bill would likely yield some health and quality-of-life improvements, such as slowing the decline of cognitive function, functional ability, and global assessment after 18 months of treatment among the 23 additional enrollees who would newly have access to and use disease-modifying medications.
- SUPPORT. The Alzheimer’s Association is sponsoring this bill, stating that it expedites access for monoclonal antibody therapies that target amyloid plaque buildup in the brain to reduce cognitive decline. The Alzheimer’s Association continues that these are among the first disease modifying treatments to become available for Alzheimer’s disease, and alongside blood-based biomarker testing and new research have encouraged early detection and diagnosis of Alzheimer’s disease. The Alzheimer’s Association argues that this legislation provides needed clarity in state law to ensure uninterrupted coverage for these new developments, so individuals do not unnecessarily exit their eligibility window and advance in the disease progression, which can involve higher costs and levels of care.
- OPPOSITION. The California Association of Health Plans (CAHP) and the Association of California Life & Health Insurance Companies (ACLHIC) write in opposition stating that even though this bill permits plans/insurers to apply utilization management like prior authorization, the bill requires that all products to treat Alzheimer’s be included on formularies, forcing plans to adjust their current coverage, impacting health care affordability. CAHP and ACLHIC continue that this bill prevents plans from updating their policies as new data emerges and from designing policies that are both affordable and appropriate for a specific diagnosis. CAHP and ACLHIC cite the CHBRP analysis, which noted there is “some evidence that disease-modifying medications are effective at slowing cognitive decline” but adds that “these effects generally fell below minimum clinically important difference thresholds.” CAHP and ACLHIC are concerned that due to the intensive treatment requirements, potential of severe side effects, and limited amount of providers who have experience prescribing and providing this treatment, this bill will accelerate utilization of these drugs before their value is proven and the infrastructure for treatment is available. Finally, CAHP and ACLHIC are concerned with the recent amendment that requires anti-amyloids and other Alzheimer’s drugs to be treated as an exigent circumstance. CAHP and ACLHIC conclude that 24-hour review is an incredibly short timeline for an entire class of drugs, specifically ones (like anti-amyloids) that are new to the market and required to be used under strict guidelines and supervision.
- PREVIOUS LEGISLATION.
- SB 496 (Limón) Chapter 496, Statutes of 2023, requires Medi-Cal, and, health plans and insurers to cover medically necessary biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of an enrollee’s or insured’s disease or condition to guide treatment decisions only if the test is supported by medical and scientific evidence, as specified.
- SB 48 (Limón) Chapter 484, Statutes of 2021, requires an annual cognitive health assessment be a covered benefit for Medi-Cal beneficiaries who are 65 years of age or older and not otherwise eligible for a similar assessment as part of the Medicare program. This bill also requires the Department of Health Care Services to determine the training and validated tools for Medi-Cal providers to render and receive payment for the covered benefit.
- PROPOSED AMENDMENTS. While health plans do not have to maintain all drugs on their prescription drug formularies, they must cover all medically necessary drugs under existing law. Language in this bill could potentially undermine that protection by limiting the definition of coverage of medically necessary drugs for Alzheimer’s. To ensure this bill isn’t weakening existing law, the committee may wish to make the following amendment to the bill:
(a) (1) A health care service plan contract that is issued, amended, or renewed on or after January 1, 2027, shall include coverage for all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease or other related dementia. Medically necessary treatments or medications include, but are not limited to, those that reduce clinical decline.
(2) Medically necessary treatments or medications covered pursuant to paragraph (1) include those administered through a medical benefit, an outpatient prescription drug benefit to the extent the health care service plan contract covers outpatient prescription drugs, or both.
(3) Coverage for all medically necessary treatment or medications pursuant to paragraph (1) does not require a health care service plan contract to cover drugs or treatments that are pharmaceutically equivalent drug products if the FDA approves more than one medication or treatment that are pharmaceutically equivalent drug products, unless otherwise required by law.
REGISTERED SUPPORT / OPPOSITION:
Support
Alzheimer's Association (sponsor)
AIDS Healthcare Foundation
Alzheimer's Greater Los Angeles
Alzheimer's Orange County
Alzheimer's San Diego
American Federation of State, County and Municipal Employees, AFL-CIO
Biocom
California Alliance for Retired Americans
California Assisted Living Association
California Chronic Care Coalition
California Coalition on Family Caregiving
California Life Sciences Association
Disability Rights California
LeadingAge California
Western Center on Law & Poverty
Opposition
Association of California Life & Health Insurance Companies
California Association of Health Plans
Analysis Prepared by: Riana King / HEALTH / (916) 319-2097
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-4171 | SB 950 |
THIRD READING
Bill No: SB 950
Author: Weber Pierson (D), et al.
Amended: 4/20/26
Vote: 21
SENATE HEALTH COMMITTEE: 9-0, 4/15/26
AYES: Weber Pierson, Valladares, Caballero, Durazo, Gonzalez, Grove, Padilla, Rubio, Smallwood-Cuevas
NO VOTE RECORDED: Menjivar, Pérez
SENATE APPROPRIATIONS COMMITTEE: 7-0, 4/27/26
AYES: Cervantes, Seyarto, Cabaldon, Dahle, Grayson, Richardson, Wahab
SUBJECT: Health care coverage: dementia
SOURCE: Alzheimer’s Association
DIGEST:
This bill requires health plans and insurers to cover all medically necessary treatments or medications, as determined by a health care provider, that are approved by the federal Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease or other related dementia. Prohibits health plans and insurers from imposing step therapy protocols when one or more medications are approved by the FDA, unless a plan or insurer has covered at least one anti-amyloid therapy without step therapy.
ANALYSIS:
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act) and the California Department of Insurance (CDI) to regulate health insurers under the Insurance Code. [Health and Safety Code (HSC) §1340, et seq. and Insurance Code (INS) §106, et seq.]
- Establishes a requirement, under federal regulations, that health plans and insurers have a process for review, upon request, of a decision that a drug is not covered by a plan. Requires notification of the determination within 72 hours of the request, or 24 hours based on exigent circumstances. Requires health plans and insurers to have a process for external review of denials of a standard exception, or for an expedited exception. [45 Code of Federal Regulations (CFR) §156.122]
- Permits health plans and insurers to require step therapy and prior authorization and defines step therapy as a type of protocol that specifies the sequence in which different prescription drugs for a given medical condition that are medically appropriate for a particular patient are to be prescribed. Includes utilization review organizations that perform utilization review or utilization management functions. [HSC §1342.71 and §1367.206, Title 28 California Code of Regulations (CCR) §1300.67.205, and INS §10123.193 and §10123.201]
- Requires a health plan contract that provides coverage for outpatient prescription drugs to cover medically necessary prescription drugs, including nonformulary drugs determined to be medically necessary consistent with the Knox-Keene Act. Excludes specified drugs such as drugs for cosmetic purposes and indicates drugs for mental performance are not excluded when they are used to treat diagnosed mental illness or medical conditions affecting memory, including, but not limited to treatment of the conditions or symptoms of dementia or Alzheimer’s disease. [HSC §1342.71, Title 28, CCR §1300.67.24 and INS §10123.193]
This bill:
- Requires a health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2027, to include coverage for all medically necessary treatments or medications, as determined by a health care provider, that are approved by the FDA for the treatment of Alzheimer’s disease or other related dementia. Indicates medically necessary treatments or medications include, but are not limited to, those that reduce clinical decline.
- Indicates medically necessary treatments or medications include those administered through a medical benefit, an outpatient prescription drug benefit to the extent the plan contract or policy covers outpatient prescription drugs, or both.
- Indicates coverage for all medically necessary treatments or medications does not require a plan contract or policy to cover drugs or treatments that are pharmaceutically equivalent drug products if the FDA approves more than one medication or treatment that are pharmaceutically equivalent drug products, unless otherwise required by law.
- Prohibits a health plan or health insurer from imposing step therapy protocols as a prerequisite to authorizing coverage of medically necessary treatments or medications approved by the FDA for the treatment of Alzheimer’s disease, except as provided in 5) below. Prohibits step therapy for both self-administered drugs and physician-administered drugs, except as provided in 5) below.
- Permits a health plan or health insurer to cover only one anti-amyloid therapy (disease modifying medication) without step therapy if the FDA has approved one or more types of treatment for Alzheimer’s disease or other medical conditions affecting memory.
- Permits a health plan or insurer to apply utilization management, including prior authorization, to determine medical necessity for the treatment of Alzheimer’s or other medical conditions affecting memory, if appropriateness and medical necessity determinations are made in the same manner as treatment of any other illness, condition, or disorder covered by the plan contract or insurance policy.
- Prohibits coverage criteria for FDA-approved treatments from being more restrictive than the FDA-approved indications for those treatments.
- Requires health plan and insurer authorization to be considered an exigent circumstance, consistent with existing law.
- Exempts a specialized health plan or insurer that covers only dental, vision, or Medicare supplement contracts or policies, Medi-Cal managed care plan contracts with Department of Health Care Services, as specified, accident-only, specified disease, or hospital indemnity policies.
Comments
According to the author of this bill: Alzheimer's disease, while often thought of as a condition of aging, reflects broader disparities in our public health system. Californian women, lower-income Californians, and Californians of color face disproportionately elevated risks, higher diagnosis rates, and poorer outcomes once living with the disease. This devastating diagnosis is life- and community-changing. As Alzheimer’s progresses, individuals lose independence and the memories that connect them to their loved ones. Families often sacrifice their livelihoods to become caregivers while navigating a complex health system. During one of the most difficult times in their lives, California cannot allow barriers to delay or prevent access to appropriate treatment. Today, FDA-approved therapies offer new hope by slowing the progression of Alzheimer’s disease in its early stages. Removing the plaque responsible for progression can preserve precious time, memories, and quality of life. But, because they are only effective early in the disease, any delays can take away the opportunity to receive this treatment altogether. As a state, we must ensure timely access to these treatments and alleviate pressure from our families and healthcare system. Families deserve more time and support when navigating Alzheimer’s.
Background California Health Benefits Review Program (CHBRP) report.
Background on Alzheimer’s disease. Alzheimer’s disease is a progressive, irreversible neurologic condition that damages and destroys neurons in the brain, and as the disease progresses, memory, language, and cognitive processing challenges are often the first symptoms to emerge. Patients may live up to ten years or longer after diagnosis. There is no cure or treatment to reverse the disease. In 2020, for California there were an estimated 719,700 adults aged 65+ living with Alzheimer’s, 547,629 of them were over 75 years old. In 2022, 17,363 people in California died from Alzheimer’s disease. For people with early-onset Alzheimer’s disease (occurring in people ages 34 to 64) the estimated prevalence in the U.S. is 31.8 people out of 100,000, or 40,326 people. Risk increases with age, with the highest risk for patients ages 85+. Women and people who are African American, Latino and Hispanic are at higher risk. People who are African American, Latino, and Hispanic are more likely to experience delays in receiving a diagnosis of dementia than white people. Barriers to receiving a diagnosis for Alzheimer's disease and accessing disease-modifying medications are substantial and may be attributed in part to the limited supply of treating clinicians who have experience prescribing the disease-modifying medications. Additionally, eligibility to receive disease-modifying medications is narrow, requires special testing that may be challenging to access, and may only be available in specialized facilities that treat a limited number of patients each year.
Coverage impacts and enrollees covered. According to CHBRP, of the 22.8 million enrolled in state-regulated health insurance, this bill would impact 13.8 million, as Medi-Cal managed care plans are exempt from this bill. Another 15 million Californians would not be covered because they are either uninsured, or have coverage that is not state regulated, such as Medicare or other federally regulated employer coverage. No enrollees have fully compliant coverage, however 88% of enrollees have coverage for disease-modifying medication under their medical benefit and 93% of enrollees have coverage of three out nine medications for treatment of symptoms.
Medi-Cal and Medicare. Medi-Cal Rx provides coverage for some medications to treat Alzheimer’s and related dementia, and Medi-Cal managed care plans also provide coverage for the two currently available anti-amyloid medications. Medicare also covers both anti-amyloid medications under the Medicare Part B benefit. Cost sharing applies depending upon type of Medicare coverage (traditional Medicare or Medicare Advantage). Medicare Part D plans must cover at least two drugs used to treat Alzheimer’s symptoms.
Medical effectiveness. Evidence for medications to treat symptoms. Medications used to treat symptoms of Alzheimer’s disease demonstrate generally small and inconsistent effects across medications, severity of disease, and outcomes.
Treatment to modify disease. Disease-modifying medications are only available for patients who meet certain clinical criteria. Those criteria include having mild cognitive impairment or mild dementia due to Alzheimer’s disease, and a confirmed presence of amyloid pathology (such as through positron emission tomography [PET] brain scan, lumbar puncture, or blood test). Additionally, patients who are unable to safely undergo MRI, or those with certain pre-existing medical conditions may be considered ineligible for these treatments. Enrollees can use medications to treat symptoms and disease-modifying medications concurrently. There is no duration limit for how long enrollees can take the medications to treat symptoms. The disease-modifying medications (anti-amyloids) are intravenous infusions that are usually administered for around 18 months, with the option to extend using a subcutaneous version for one of the medications. Periodic MRIs are required prior to, during, and after the conclusion of treatment for safety monitoring.
Evidence for disease-modifying medications. There is strong evidence that disease-modifying medications are effective at reducing or clearing amyloid plaque and demonstrate robust and consistent effects on amyloid biomarkers. There is some evidence that disease modifying medications are effective at slowing cognitive decline, functional decline, and combined measures of cognitive and functional decline by a small amount. However, effect sizes were generally modest, and most findings did not meet thresholds for clinical meaningfulness. There is some evidence that disease-modifying medications are associated with increased risk of harm. All studies consistently demonstrated higher rates of amyloid-related imaging abnormalities and hemorrhage, including microhemorrhages and superficial siderosis, among treated participants, in initial treatment period. Most events were asymptomatic and detected through imaging, although symptomatic cases occurred in a smaller proportion of participants. Mortality rates were low and similar to placebo groups, with no clear evidence of increased mortality risk. Other adverse events, such as infusion-related reactions, were common and manageable but led to discontinuation in a subset of participants. Some reactions, such as intracerebral hemorrhage, have the potential to result in sever disability or death.
Health improvement. There is not enough research to determine whether amyloid plaque reduction improves health outcomes. Findings suggest that amyloid reduction is associated with a statistically significant but small improvement in cognitive and combined measure outcomes, but the small effect sizes did not meet the threshold for minimum clinically important differences.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Senate Appropriations Committee, DMHC anticipates minor and absorbable costs for state administration (Managed Care Fund). CDI estimates costs of $11,000 in 2026-27 and $23,000 in 2027-28 for state administration (Insurance Fund).
SUPPORT: (Verified 4/27/26)
Alzheimer’s Association (source)
AIDS Healthcare Foundation
Alliance for Patient Access
Alzheimer’s Greater Los Angeles
Alzheimer’s Orange County
Alzheimer’s San Diego
American Federation of State, County, and Municipal Employees
Association of California Healthcare Districts
Biocom California
California Alliance for Retired Americans
California Assisted Living Association
California Black Health Network
California Chronic Care Coalition
California Coalition on Family Caregiving
California Life Sciences
California Long Term Care Ombudsman Association
California PACE Association
Family Caregiver Alliance
LeadingAge California
Multipurpose Senior Services Program Site Association
Western Center on Law & Poverty, Inc.
One individual
OPPOSITION: (Verified 4/27/26)
Association of California Life & Health Insurance Companies
California Association of Health Plans
ARGUMENTS IN SUPPORT: This bill’s sponsor, the Alzheimer’s Association, writes that “this legislation expedites access for monoclonal antibody therapies that target amyloid plaque buildup in the brain to reduce cognitive decline. These are among the first disease modifying treatments to become available for Alzheimer’s disease. The advent of these treatments along with blood-based biomarker testing and new research on lifestyle interventions’ efficacy staving off cognitive decline have encouraged early detection and diagnosis of Alzheimer’s disease. Perspectives have changed because these developments provide proactive measures to manage cognitive decline for individuals contending with a diagnosis. Presently, these therapies are only available for those in the early stage of Alzheimer’s disease, making access crucial.”
ARGUMENTS IN OPPOSITION: The California Association of Health Plans (CAHP) and the Association of California Life and Health Insurance Companies (ACLHIC) indicate that the demonstrated effectiveness of anti-amyloids has not been clearly substantiated, and they reference CHBRP statements that there is not enough research to determine whether amyloid plaque reduction improves health outcomes and that the small effect sizes did not meet the threshold for minimum clinically important differences. They are also concerned that this bill will accelerate utilization of these drugs before their value is proven and the infrastructure for treatment is available. Regarding the step therapy requirement, CAHP and ACLHIC are concerned that it further grants immediate access to a drug that has not been proven to improve health outcomes, which is a concern because an individual course of treatment is between $26,500 - $32,000.
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
4/29/26 16:22:15
SENATE COMMITTEE ON
Senator Sabrina Cervantes, Chair
2025 - 2026 Regular Session
SB 950 (Weber Pierson) - Health care coverage: dementia
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
Bill Summary:
SB 950 would require health plans and insurers to cover all medically necessary treatments or medications for the treatment of Alzheimer’s disease or other related dementia, as specified.
Fiscal Impact:
- The Department of Managed Health Care (DMHC) anticipates minor and absorbable costs for state administration (Managed Care Fund).
- The California Department of Insurance (CDI) estimates costs of $11,000 in 2026-27 and $23,000 in 2027-28 for state administration (Insurance Fund).
Background:
According to the California Health Benefits Review Program (CHBRP), medication treatments for Alzheimer’s disease include medications that treat symptoms of the disease and disease-modifying medications that aim to slow the rate of disease progression. At this time, disease-modifying medications are only available for patients who meet certain clinical criteria.
California law requires plans and policies to cover all mental health and substance use disorders listed in the most recent edition of either the International Classification of Disease or the Diagnostic and Statistical Manual of Mental Disorders at parity with other medical services. The CHBRP indicates that Alzheimer’s disease is recognized in the Diagnostic and Statistical Manual of Mental Disorders under “Dementia of the Alzheimer’s Type.” Therefore, treatment for Alzheimer’s disease is required to be covered at parity with other medical services, although not all medications would need to be included “on formulary,” and there is no requirement for plans and policies to cover all therapeutically equivalent medications.
CHBRP indicates that in general, drugs that are physician-ordered and administered under the supervision of a physician (generally in a hospital, a provider’s office, infusion center, or similar medical facility), along with the hospital stay or office visit, are generally covered through health coverage as a medical benefit. Pharmacy benefits typically cover outpatient prescription drugs by covering prescriptions that are generally filled at a retail pharmacy, a mail-order pharmacy, or a specialty pharmacy. Current law requires health plans and insurers that perform utilization review or utilization management functions based on medical necessity requests to comply with specified requirements. Current law permits health plans and insurers to require step therapy and prior authorization for prescription drugs.
Proposed Law:
Specific provisions of the bill would:
- Require health plans and insurers to cover all medically necessary treatments or medications, as determined by a health care provider, approved by the United States Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease or other related dementia; specify that medically necessary treatments or medications include, but are not limited to, those that reduce clinical decline; provide that medically necessary treatments or medications covered include those administered through a medical benefit, an outpatient prescription drug benefit to the extent the health plan/insurer covers outpatient prescription drugs, or both; and provide that coverage for all medically necessary treatment or medications does not require a health plan/insurer to cover drugs or treatments that are pharmaceutically equivalent drug products if the FDA approves more than one medication or treatment that are pharmaceutically equivalent drug products, unless otherwise required by law.
- Prohibit a health plan or insurer from imposing step therapy protocols as a prerequisite to authorizing coverage of medically necessary treatments or medications approved by the FDA for the treatment of Alzheimer’s disease, except as provided.
- Permit health plans and insurers to apply utilization management, including prior authorization, to determine the medical necessity for treatment of Alzheimer’s or other medical conditions affecting memory if appropriateness and medical necessity determinations are made in the same manner as those determinations are made for the treatment of any other illness, condition, or disorder covered by the plan/insurer.
- Exempt Medi-Cal managed care plan contracts.
Staff Comments:
According to the CHBRP analysis of SB 950 (introduced version), for DMHC-regulated plans and CDI-regulated policies, the bill would increase total premiums paid by employers and enrollees for newly covered benefits by $660,000. This includes an increase of $3,000 for CalPERS employer premiums. CHBRP indicates that the long-term cost implications of SB 950 could be substantial as new drugs come to market. Because SB 950 requires coverage of all Alzheimer’s-related drugs, new branded drugs that come to market would be covered. However, because health plans and insurers could still use prior authorization requirements that require imaging and could act as a barrier to use, cost increases might be mitigated by strict prior authorization requirements despite the ban on step therapy.
-- END --
SENATE COMMITTEE ON HEALTH
Senator Dr. Akilah Weber Pierson, Chair
BILL NO: SB 950
AUTHOR: | Weber Pierson | ||
VERSION: | February 2, 2026 | ||
HEARING DATE: | April 15, 2026 | ||
CONSULTANT: | Teri Boughton | ||
SUBJECT: Health care coverage: dementia
SUMMARY:
Requires health plans and insurers to cover all medically necessary treatments or medications, as determined by a health care provider, that are approved by the federal Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease or other related dementia. Prohibits health plans and insurers from imposing step therapy protocols when one or more
medications are approved by the FDA, unless a plan or insurer has covered at least one anti-amyloid therapy without step therapy. Requires a plan or insurer to cover non-self-administered treatments approved by the FDA as an outpatient prescription drug benefit if covered as a medical benefit.
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act) and the California Department of Insurance (CDI) to regulate health insurers under the Insurance Code. [HSC §1340, et seq. and INS §106, et seq.]
- Requires health plans and insurers, and any contracted entity that performs utilization review or utilization management functions, prospectively, retrospectively, or concurrently, based on medical necessity requests to comply with specified requirements, including a decision within five business days of receiving reasonable information to make a decision, conducting retrospective review within 30 days and decisions associated with imminent and serious threat within 72 hours or sooner. [HSC §1367.01 and INS §10123.135]
- Establishes a requirement, under federal regulations, that health plans and insurers have a process for review, upon request, of a decision that a drug is not covered by a plan. Requires notification of the determination within 72 hours of the request, or 24 hours based on exigent circumstances. Requires health plans and insurers to have a process for external review of denials of a standard exception, or for an expedited exception. [45 CFR §156.122]
- Permits health plans and insurers to require step therapy and prior authorization and defines step therapy as a type of protocol that specifies the sequence in which different prescription drugs for a given medical condition that are medically appropriate for a particular patient are to be prescribed. Includes utilization review organizations that perform utilization review or utilization management functions. [HSC §1342.71 and §1367.206, Title 28 CCR §1300.67.205, and INS §10123.193 and §10123.201]
- Requires a health plan contract that provides coverage for outpatient prescription drugs to cover medically necessary prescription drugs, including nonformulary drugs determined to be medically necessary consistent with the Knox-Keene Act. Excludes specified drugs such as drugs for cosmetic purposes and indicates drugs for mental performance are not excluded when they are used to treat diagnosed mental illness or medical conditions affecting memory, including, but not limited to treatment of the conditions or symptoms of dementia or Alzheimer’s disease. [HSC §1342.71, Title 28, CCR §1300.67.24 and INS §10123.193]
- Requires an external exception request review process for a denial of a prior authorization or step therapy exception request. Requires an independent review organization’s reversal of a health plan or insurer denial of a request for an exception, prior authorization, or step therapy exception to be binding and apply for the duration of the prescription, and refills. [HSC §1367.241 and INS §10123.191]
- Requires every health plan contract and insurance policy that provides hospital, medical, or surgical coverage to provide coverage for medically necessary treatment of mental health and substance use disorders under the same terms and conditions applied to other medical conditions, as specified. [HSC §1374.72 and INS §10144.5]
- Requires plans and insurers that offer contracts and policies described above to base any medical necessity determination or utilization review criteria used to determine medical necessity on current generally accepted standards of mental health and substance use disorder care. [HSC §1374.721 and INS §10144.52]
- Prohibits a health plan or insurer from subjecting antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis, to prior authorization or step therapy, except if the FDA has approved one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV, in which case the plan or insurer is required to only cover one therapeutically equivalent version without prior authorization or step therapy. [HSC §1342.74 and INS §10123.1933]
This bill:
- Requires a health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2027, to include coverage for all medically necessary treatments or medications, as determined by a health care provider, that are approved by the FDA for the treatment of Alzheimer’s disease or other related dementia. Indicates medically necessary treatments or medications include, but are not limited to, those that reduce clinical decline.
- Prohibits a health plan or health insurer from imposing step therapy protocols as a prerequisite to authorizing coverage of medically necessary treatments or medications approved by the FDA for the treatment of Alzheimer’s disease, except as provided in 3) below. Prohibits step therapy for both self-administered drugs and physician-administered drugs, except as provided in 3) below.
- Permits a health plan or health insurer to cover only one anti-amyloid therapy (disease modifying medication) without step therapy if the FDA has approved one or more types of treatment for Alzheimer’s disease or other medical conditions affecting memory.
- Permits a health plan or insurer to apply utilization management, including prior authorization, to determine medical necessity for the treatment of Alzheimer’s or other medical conditions affecting memory, if appropriateness and medical necessity determinations are made in the same manner as treatment of any other illness, condition, or disorder covered by the plan contract or insurance policy.
- Prohibits coverage criteria for FDA-approved treatments from being more restrictive than the FDA-approved indications for those treatments.
- Requires plans and insurers to cover non-self-administered FDA-approved treatments as an outpatient prescription drug benefit if plans and insurers cover those FDA-approved treatments as a medical benefit.
- Requires health plans and insurers to maintain an expeditious process by which prescribing providers may obtain authorization for a medically necessary treatment approved by the FDA for the treatment of Alzheimer’s disease or other medical conditions affecting memory, consistent with existing law.
- Exempts a specialized health plan or insurer that covers only dental, vision, or Medicare supplement contracts or policies, Medi-Cal managed care plan contracts with Department of Health Care Services, as specified, accident-only, specified disease, or hospital indemnity policies.
FISCAL EFFECT:
This bill has not been analyzed by a fiscal committee.
COMMENTS:
- Author’s statement. According to the author, Alzheimer's disease, while often thought of as a condition of aging, reflects broader disparities in our public health system. Californian women, lower-income Californians, and Californians of color face disproportionately elevated risks, higher diagnosis rates, and poorer outcomes once living with the disease. This devastating diagnosis is life- and community-changing. As Alzheimer’s progresses, individuals lose independence and the memories that connect them to their loved ones. Families often sacrifice their livelihoods to become caregivers while navigating a complex health system. During one of the most difficult times in their lives, California cannot allow barriers to delay or prevent access to appropriate treatment. Today, FDA-approved therapies offer new hope by slowing the progression of Alzheimer’s disease in its early stages. Removing the plaque responsible for progression can preserve precious time, memories, and quality of life. But, because they are only effective early in the disease, any delays can take away the opportunity to receive this treatment altogether. As a state, we must ensure timely access to these treatments and alleviate pressure from our families and healthcare system. Families deserve more time and support when navigating Alzheimer’s.
- California Health Benefits Review Program (CHBRP) report. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written report with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996 and reviewed this bill.
Key findings include:- Background on Alzheimer’s disease. Alzheimer’s disease is a progressive, irreversible neurologic condition that damages and destroys neurons in the brain, and as the disease progresses, memory, language, and cognitive processing challenges are often the first symptoms to emerge. Patients may live up to ten years or longer after diagnosis. There is no cure or treatment to reverse the disease. In 2020, for California there were an estimated 719,700 adults aged 65+ living with Alzheimer’s, 547,629 of them were over 75 years old. In 2022, 17,363 people in California died from Alzheimer’s disease. For people with early-onset Alzheimer’s disease (occurring in people ages 34 to 64) the estimated prevalence in the U.S. is 31.8 people out of 100,000, or 40,326 people. Risk increases with age, with the highest risk for patients ages 85+. Women and people who are African American, Latino and Hispanic are at higher risk. People who are African American, Latino, and Hispanic are more likely to experience delays in receiving a diagnosis of dementia than white people. Barriers to receiving a diagnosis for Alzheimer's disease and accessing disease-modifying medications are substantial and may be attributed in part to the limited supply of treating clinicians who have experience prescribing the disease-modifying medications. Additionally, eligibility to receive disease-modifying medications is narrow, requires special testing that may be challenging to access, and may only be available in specialized facilities that treat a limited number of patients each year.
- Coverage impacts and enrollees covered. According to CHBRP, of the 22.8 million enrolled in state-regulated health insurance, this bill would impact 13.8 million, as Medi-Cal managed care plans are exempt from this bill. Another 15 million Californians would not be covered because they are either uninsured, or have coverage that is not state regulated, such as Medicare or other federally regulated employer coverage. No enrollees have fully compliant coverage, however 88% of enrollees have coverage for disease-modifying medication under their medical benefit and 93% of enrollees have coverage of three out nine medications for treatment of symptoms.
- Medi-Cal and Medicare. Medi-Cal Rx provides coverage for some medications to treat Alzheimer’s and related dementia, and Medi-Cal managed care plans also provide coverage for the two currently available anti-amyloid medications. Medicare also covers both anti-amyloid medications under the Medicare Part B benefit. Cost sharing applies depending upon type of Medicare coverage (traditional Medicare or Medicare Advantage). Medicare Part D plans must cover at least two drugs used to treat Alzheimer’s symptoms.
- Medical effectiveness.
- Evidence for medications to treat symptoms. Medications used to treat symptoms of Alzheimer’s disease demonstrate generally small and inconsistent effects across medications, severity of disease, and outcomes. There is strong evidence that cholinesterase inhibitors are associated with small improvements in cognitive function and global assessment (clinical assessment evaluating cognition, behavior and function) relative to placebo but do not improve functional ability. Evidence for neuropsychiatric/behavioral symptoms is conflicting. N-methyl-D-aspartate (NMDA)-receptor antagonists show no meaningful effects on cognition or functional ability but are associated with small improvements in global assessment and neuropsychiatric symptoms in patients with moderate-to-severe disease relative to placebo. Compared with cholinesterase inhibitors alone, combination therapy was associated with small improvements in cognitive function, neuropsychiatric/behavioral symptoms, and global assessment, but not in functional ability. Rates of serious adverse events did not differ between cholinesterase inhibitors and placebo and between NMDA-receptor antagonists and placebo.
- Treatment to modify disease. Disease-modifying medications are only available for patients who meet certain clinical criteria. Those criteria include having mild cognitive impairment or mild dementia due to Alzheimer’s disease, and a confirmed presence of amyloid pathology (such as through positron emission tomography [PET] brain scan, lumbar puncture, or blood test). Additionally, patients who are unable to safely undergo MRI, or those with certain pre-existing medical conditions may be considered ineligible for these treatments. Enrollees can use medications to treat symptoms and disease-modifying medications concurrently. There is no duration limit for how long enrollees can take the medications to treat symptoms. The disease-modifying medications (anti-amyloids) are intravenous infusions that are usually administered for around 18 months, with the option to extend using a subcutaneous version for one of the medications. Periodic MRIs are required prior to, during, and after the conclusion of treatment for safety monitoring.
- Evidence for disease-modifying medications. There is strong evidence that disease-modifying medications are effective at reducing or clearing amyloid plaque and demonstrate robust and consistent effects on amyloid biomarkers. There is some evidence that disease modifying medications are effective at slowing cognitive decline, functional decline, and combined measures of cognitive and functional decline by a small amount. However, effect sizes were generally modest, and most findings did not meet thresholds for clinical meaningfulness. There is some evidence that disease-modifying medications are associated with increased risk of harm. All studies consistently demonstrated higher rates of amyloid-related imaging abnormalities and hemorrhage, including microhemorrhages and superficial siderosis, among treated participants, in initial treatment period. Most events were asymptomatic and detected through imaging, although symptomatic cases occurred in a smaller proportion of participants. Mortality rates were low and similar to placebo groups, with no clear evidence of increased mortality risk. Other adverse events, such as infusion-related reactions, were common and manageable but led to discontinuation in a subset of participants. Some reactions, such as intracerebral hemorrhage, have the potential to result in sever disability or death.
- Health improvement. There is not enough research to determine whether amyloid plaque reduction improves heath outcomes. Findings suggest that amyloid reduction is associated with a statistically significant but small improvement in cognitive and combined measure outcomes, but the small effect sizes did not meet the threshold for minimum clinically important differences.
- Utilization. CHBRP relied on commercial claims data to estimate the likely prevalence of mild cognitive decline or mild dementia related to Alzheimer’s disease. It is likely to be lower than the population-level prevalence of 31.8/100,000 due to the increased likelihood that people experiencing mild cognitive impairment or mild dementia would qualify for Medi-Cal or Medicare due to short-term or long-term disability, or be
- Background on Alzheimer’s disease. Alzheimer’s disease is a progressive, irreversible neurologic condition that damages and destroys neurons in the brain, and as the disease progresses, memory, language, and cognitive processing challenges are often the first symptoms to emerge. Patients may live up to ten years or longer after diagnosis. There is no cure or treatment to reverse the disease. In 2020, for California there were an estimated 719,700 adults aged 65+ living with Alzheimer’s, 547,629 of them were over 75 years old. In 2022, 17,363 people in California died from Alzheimer’s disease. For people with early-onset Alzheimer’s disease (occurring in people ages 34 to 64) the estimated prevalence in the U.S. is 31.8 people out of 100,000, or 40,326 people. Risk increases with age, with the highest risk for patients ages 85+. Women and people who are African American, Latino and Hispanic are at higher risk. People who are African American, Latino, and Hispanic are more likely to experience delays in receiving a diagnosis of dementia than white people. Barriers to receiving a diagnosis for Alzheimer's disease and accessing disease-modifying medications are substantial and may be attributed in part to the limited supply of treating clinicians who have experience prescribing the disease-modifying medications. Additionally, eligibility to receive disease-modifying medications is narrow, requires special testing that may be challenging to access, and may only be available in specialized facilities that treat a limited number of patients each year.
unable to work and maintain health insurance benefits through an employer. Using Milliman claims data, the prevalence rate was 5.76/100,000 among the commercial enrollers with commercial health insurance subject to this bill. CHBRP estimates 66 additional enrollees will receive medications to treat symptoms (currently 1,086 enrollees are estimated to be using these treatments typically through the pharmacy benefit) and 23 additional enrollees will receive disease-modifying medications (currently 89 enrollees are using disease-modifying treatments via infusion through the medical benefit). There is a subcutaneous treatment that is typically covered on the pharmacy benefit because it is self-administered but is a weekly maintenance dose available after 18 months of infusion treatment. Those using disease-modifying medications require imaging to monitor amyloid resulting in 92 PET scans and 354 MRIs each year. CHBRP estimates at least one PET scan per year due to initial treatment requirements for new patients and monitoring needs for existing patients.
- Impact on expenditures. Total annual premiums (paid by employers and enrollees) would increase by $660,000 or up to $.03 per member per month. Enrollee cost-sharing for new users of medications who previously did not have coverage is $1,310 (small group market), $1,390 (large group market) and $1,990 (individual market), annually.
- Public health. No measurable public health impact at the population level due to the small estimated increase in utilization in the population that would be covered by this bill and eligible for the medications. However, this bill would likely yield some health and quality of life improvements, such as slowing decline of cognitive function, functional ability, and global assessment after 18 months of treatment among the 23 additional enrollees who would newly have access to and use disease-modifying medications.
- Impact on expenditures. Total annual premiums (paid by employers and enrollees) would increase by $660,000 or up to $.03 per member per month. Enrollee cost-sharing for new users of medications who previously did not have coverage is $1,310 (small group market), $1,390 (large group market) and $1,990 (individual market), annually.
- Prior legislation. SB 496 (Limón, Chapter 496, Statutes of 2023) requires Medi-Cal, and, health plans and insurers to cover medically necessary biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of an enrollee’s or insured’s disease or condition to guide treatment decisions only if the test is supported by medical and scientific evidence, as specified.
SB 48 (Limón, Chapter 484, Statutes of 2021) requires an annual cognitive health assessment be a covered benefit for Medi-Cal beneficiaries who are 65 years of age or older and not otherwise eligible for a similar assessment as part of the Medicare program. This bill also requires the Department of Health Care Services to determine the training and validated tools for Medi-Cal providers to render and receive payment for the covered benefit.
- Support. This bill’s sponsor, the Alzheimer’s Association, writes that “this legislation expedites access for monoclonal antibody therapies that target amyloid plaque buildup in the brain to reduce cognitive decline. These are among the first disease modifying treatments to become available for Alzheimer’s disease. The advent of these treatments along with blood-based biomarker testing and new research on lifestyle interventions’ efficacy staving off cognitive decline have encouraged early detection and diagnosis of Alzheimer’s disease. Perspectives have changed because these developments provide proactive measures to manage cognitive decline for individuals contending with a diagnosis. Presently, these therapies are only available for those in the early stage of Alzheimer’s disease, making access crucial. This legislation provides needed clarity in state law to ensure uninterrupted coverage for these new developments, so individuals do not unnecessarily exit their eligibility window and advance in the disease progression, which can involve higher costs and levels of care.” The Association of California Healthcare Districts (ACHD) writes that these therapies have encouraged individuals to seek early detection and diagnosis and that they along with lifestyle interventions can measurably delay cognitive decline. ACHD believes this can result in individuals aging in place for longer periods of time, and less utilization of services as the disease progresses. The California Long-Term Care Ombudsman Association writes that this bill recognizes the importance of early intervention by improving access to treatments through coverage and reduced administrative barriers.
- Opposition. The California Association of Health Plans (CAHP) and the Association of California Life and Health Insurance Companies (ACLHIC) write that this bill would categorize provider-administered drugs as outpatient prescription drug benefits despite that they are not self-administered and are delivered in clinical settings, and, that reclassifying these drugs in this manner is inconsistent with longstanding industry standards and could create operational and administrative challenges. The opponents say this would set a concerning precedent. The opponents also write having all FDA approved drugs covered under both the medical and pharmacy benefit prevents plans and insurers from updating their formularies as new data emerges and limits plans and insurers from designing products that are both affordable and appropriate for a specific diagnosis. CAHP and ACLHIC also indicate that the demonstrated effectiveness of anti-amyloids has not been clearly substantiated, and they reference CHBRP statements that there is not enough research to determine whether amyloid plaque reduction improves health outcomes and that the small effect sizes did not meet the threshold for minimum clinically important differences. They are also concerned that this bill will accelerate utilization of these drugs before their value is proven and the infrastructure for treatment is available. Regarding the step therapy requirement, CAHP and ACLHIC are concerned that it further grants immediate access to a drug that has not been proven to improve health outcomes, which is a concern because an individual course of treatment is between $26,500 - $32,000.
- Policy comments regarding expeditious prior authorization process. In existing law an expeditious prior authorization process is required for requests for coverage of nonformulary drug coverage. The process is not standardized and is subject to each plan’s policy which must be filed with DMHC. If a more transparent and standardized process for prior authorization decisions is desired, the author may wish to utilize the existing prior authorization timeframes of 72 hours for nonurgent requests and 24 hours for exigent circumstances.
SUPPORT AND OPPOSITION:
Support: Alzheimer’s Association (sponsor)
Alliance for Patient Access
Alzheimer’s Greater Los Angeles
Alzheimer’s Orange County
Alzheimer’s San Diego
American Federation of State, County, and Municipal Employees
Association of California Healthcare Districts
Biocom California
California Alliance for Retired Americans
California Assisted Living Association
California Black Health Network
California Chronic Care Coalition
California Coalition on Family Caregiving
California Life Sciences
California Long Term Care Ombudsman Association
Family Caregiver Alliance
LeadingAge California
Multipurpose Senior Services Program Site Association
Western Center on Law & Poverty, Inc.
One individual
Oppose: Association of California Life & Health Insurance Companies
California Association of Health Plans
-- END --
Discussed in Hearing
Senate Floor
Assembly Floor
Assembly Standing Committee on Health
Senate Floor
Senate Standing Committee on Appropriations
Senate Standing Committee on Health
Bill Author
Bill Co-Author(s):